Hypersensitivity Adverse Event Reporting in Clinical Cancer Trials: Barriers and Potential Solutions to Studying Severe Events on a Population Level by Eldredge, Christina E.
University of Wisconsin Milwaukee 
UWM Digital Commons 
Theses and Dissertations 
May 2020 
Hypersensitivity Adverse Event Reporting in Clinical Cancer Trials: 
Barriers and Potential Solutions to Studying Severe Events on a 
Population Level 
Christina E. Eldredge 
University of Wisconsin-Milwaukee 
Follow this and additional works at: https://dc.uwm.edu/etd 
 Part of the Library and Information Science Commons, and the Medicine and Health Sciences 
Commons 
Recommended Citation 
Eldredge, Christina E., "Hypersensitivity Adverse Event Reporting in Clinical Cancer Trials: Barriers and 
Potential Solutions to Studying Severe Events on a Population Level" (2020). Theses and Dissertations. 
2371. 
https://dc.uwm.edu/etd/2371 
This Dissertation is brought to you for free and open access by UWM Digital Commons. It has been accepted for 
inclusion in Theses and Dissertations by an authorized administrator of UWM Digital Commons. For more 







HYPERSENSITIVITY ADVERSE EVENT REPORTING IN CLINICAL CANCER TRIALS:  
BARRIERS AND POTENTIAL SOLUTIONS TO STUDYING SEVERE EVENTS ON A 
POPULATION LEVEL 




A Dissertation Submitted in 
 Partial Fulfillment of the 
 Requirements for the Degree of 
 
Doctor in Philosophy 
in Biomedical and Health Informatics 
 
at 





HYPERSENSITIVITY ADVERSE EVENT REPORTING IN CLINICAL CANCER TRIALS:  






The University of Wisconsin-Milwaukee, 2020 
Under the Supervision of Professor Timothy Patrick 
 
Clinical cancer trial interventions are associated with hypersensitivity events (HEs) which are 
recorded in the national clinical trial registry, ClinicalTrials.gov and publicly available.  This 
data could potentially be leveraged to study predictors for HEs to identify at risk patients who 
may benefit from desensitization therapies to prevent these potentially life-threatening reactions.  
However, variation in investigator reporting methods is a barrier to leveraging this data for 
aggregation and analysis.  The National Cancer Institute has developed the CTCAE classification 
system to address this barrier.  This study analyzes the comprehensiveness of CTCAE to 
describe severe HEs in clinical cancer trials in comparison to other systems or terminologies. 
 
An XML parser was used to extract readable text from adverse event tables.  Queries of the 
parsed data elements were performed to identify immune disorder events associated with 
biological and chemotherapy interventions.  A data subset of severe anaphylactic and 
anaphylactoid events was created and analyzed. 
  
1,331 clinical trials with 13088 immune disorder events occurred from September 20, 1999 to 
March 2018.  2409 (18.4%) of these were recorded as “serious” events.  In the severe subset, 
MedDRA terminology, CTCAE or CTC classification systems were used to describe HEs, 
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however, a large number of studies did not specify the system. The CTCAE term “anaphylaxis” 
was miscoded as “other (not including serious)” in 76.2% of events.  The CTCAE classification 
system severity grades levels were not used to describe any of the severe events and the majority 
of terms did not include the allergen and therefore, in dual or multi- drug therapies, the etiologic 
agent was not identifiable.  Furthermore, collection methods were not specified in 76% of 
events.   
 
Therefore, CTCAE was not found to improve the ability to capture event etiology or severity in 
anaphylaxis and anaphylactoid events in cancer clinical trials.  Potential solutions to improving 
CTCAE HE description include adapting terms with a low percentage of HE severity miscoding 
(e.g. anaphylactic reaction) and terms which include drugs, biological agents and/or drug classes 
to improve study of anaphylaxis etiology and incidence in multi-drug cancer therapy, therefore, 
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CHAPTER ONE:  INTRODUCTION 
 
 
This study aims to analyze the feasibility to study severe hypersensitivity events secondary to 
clinical cancer trial drug and biological agent interventions, identify barriers to conducting 
population-level analysis of these adverse events, and suggest potential practical solutions to 
address the barriers.  A preliminary analysis of publicly available data in clinicaltrails.gov 
revealed significant challenges to population-level analysis of hypersensitivity events across 
clinical trials due to variation in clinical trial reporting data collection methods, lack of 
information on the etiology (antigen) of the event, temporal information, and lack of granularity 
(lower level terms) available to code hypersensitivity allergic events in certain controlled 
terminologies and classification systems.  Furthermore, the complex nature of cancer 
interventions with several drugs and/or agents involved in one clinical trial arm compounded the 
problem of characterizing the hypersensitivity events.  The National Cancer Institute has 
developed five severity “grade” levels with their Common Terminology Criteria for Adverse 
Events (CTCAE) classification system (National Cancer Institute, 2006) to address this barrier, 
however, the preliminary analysis of the data revealed that these grades are not regularly used in 
reporting hypersensitivity events in this dataset. (Eldredge, Singavi, Lam, Gallagher, & Luo, 
2018)  Furthermore, the literature notes the unique challenges of using controlled terminology or 
classification systems to capture hypersensitivity events, especially allergic events. (Goss, et al., 
2013)   Therefore, it is hypothesized that lack of granularity with regards to documenting the 
antigen and accurate identification of severity in adverse hypersensitivity event reporting in dual 
and multi drug and/or biological agent therapy interventions hinders the ability to identify and 
study the incidence of these events, specifically in a case study of severe anaphylaxis and 
anaphylactoid reactions with cancer therapy interventions, across clinical trials.    
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To test this theory, this study will first analyze the current state of hypersensitivity adverse event 
reporting in cancer clinical therapy using data from clinicaltrials.gov.  The scope of the study 
will be focused on hypersensitivity events which are categorized as immune disorder events by 
the National Cancer Institute (NCI) and a case study of a subset of severe hypersensitivity 
adverse events, specifically anaphylactic and anaphylactoid events which are severe immediate 
life-threatening adverse events.  Variation in terminology use and gaps in reporting the antigen 
etiology (referred to as “allergen” in reference to purely allergic events in this study) and adverse 
event severity will be analyzed to inform future secondary use of the data for population level 
analysis, future terminology or classification system improvements, and semantic mapping of 
hypersensitivity events. 
 
Cancer incidence is increasing and may surpass diseases of the heart as the most common cause 
of death in the United States (National Vital Statistics, 2017). New initiatives, such as the 
National Cancer Institute Cancer Moonshot, aim to expedite and streamline research to find a 
cure for this devastating disease (Institute, 2018).  As a result, several new anti-cancer therapies 
are being approved by the U.S. Federal Food and Drug Administration through a “fast track 
process” (U.S. Food & Drug Administration, 2018).  Furthermore, new research and 
development is increasing the number of available drugs and therapies, especially biological 
immune therapies.  However, cancer therapy, especially chemotherapy and biological therapies, 
are known to be associated with severe adverse events, especially severe hypersensitivity events, 
often referred to anaphylaxis or anaphylactoid reactions. (Giavina-Bianchi, Patil, & Banerji, 
2017).  Despite this, few predictive risk factors are known, however, several possible risk factors 
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for severe anaphylactic reactions are being studied such as age, gender, vigorous exercise and 
certain drugs and biological agents. (Worm, et al., 2018)  Furthermore, new methods for 
treatment such as drug desensitization therapy can be used to prevent these potentially life-
threatening events, however, prior risk identification would inform potential candidates. 
(Bonamichi-Santos & Castells, 2018) 
 
ClinicalTrails.gov is one of the largest databases of clinical trial data, both publicly and privately 
funded. (ClinicalTrials.gov, 2018)  This registry has steadily grown since the year 2000, 
incorporating increasing requirements for clinical trial outcomes and adverse event reporting.  
Currently, all adverse events, including hypersensitivity events, in ClinicalTrails.gov, are 
recorded by the clinical trial investigator team using their collection assessment method and 
terminology or classification system of choice. (U.S. National Library of Medicine, 2017)  Since 
investigators vary in their data collection assessment methods and choice of controlled 
terminology for data reporting, significant barriers exist to the secondary analysis of this data on 
a population level to support studies on risks factors for hypersensitivity events in cancer trials.  
In addition, the comprehensiveness of each terminology, to capture allergy event severity, 
allergen, acuteness and recurrence varies significantly, compounding the problem.  (Goss et al, 
2013) In this study, adverse allergic events were extracted from semi-structured tables in 
ClinicalTrials.gov from the time period of 1999 through 2018 using an XML parser.  The 
terminology used to describe these events was analyzed for the presence of descriptors 
specifically:  allergen, severity, acuteness and reoccurrence.  Additionally, the collection and 
assessment method used by each investigator was examined.    
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The following research questions and hypotheses was used in analyzing the data: 
 
Research Question:  
Is the use of National Cancer Institute CTCAE Classification System, with its ability to grade 
severity of adverse events, improving the ability to aggregate clinical trial data to study the 
incidence, etiology and severity of severe hypersensitivity events secondary to cancer biological 
and/or chemotherapeutic agents on a population level (across clinical trials) in comparison to the 
use of MedDRA? 
 
Hypothesis #1:  
The ability to accurately record severity of anaphylactic and anaphylactoid events secondary to 
cancer biological and/or chemotherapy agents is improving with the use of the CTCAE 
classification system and its emphasis on severity grades in comparison to MedDRA. 
 
Hypothesis #2:   
Terms used to describe severe anaphylactic and anaphylactoid events recorded in the dataset of 
clinical cancer trials from ClinicalTrials.gov rarely (<5% of events) include the antigen 
responsible for the event which hinders the ability to study incidence of drug and biological 
agent induced hypersensitivity events when the clinical trial intervention includes multiple drugs 
and/or multiple therapeutic agents.  In other words, there is no statistical difference between the 
types of terminologies or classification systems used regarding the inclusion of the antigen 
within the severe hypersensitivity event term. 
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Hypothesis #3:   
Over 25% of the severe anaphylactic and anaphylactoid events have not been recorded using a 























CHAPTER TWO:  BACKGROUND AND LITERATURE REVIEW 
 
Definitions and classification of adverse drug reactions 
Adverse drug reactions (ADRs) fall under adverse drug events (AEs).  The FDA Guideline for 
Industry, “Clinical Safety Data Management:  Definitions and Standards for Expedited 
Reporting”, defines as adverse event as the following:  “Any untoward medical occurrence in a 
patient or clinical investigation subject administered a pharmaceutical product and which does 
not necessarily have to have a causal relationship with this treatment.” (FDA, 1995)  The FDA 
further breaks down this category into serious and severe events.  Severity of events are 
documented by intensity (e.g. mild, moderate, or severe), in contrast to seriousness of the event, 
which are coded by the patient outcome. (FDA, 1995) 
 
In the academic allergy community, adverse drug reactions (ADRs) are defined by the Joint Task 
Force on Practice Parameters (which includes the American Academy of Allergy, Asthma and 
Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council 
of Allergy, Asthma and Immunology) as any inadvertent drug reactions which are not intentional 
abuse or overdose, the result of an error in medication administration or “therapeutic failures”.  
The incidence of ADRs is approximately 10% in hospitalized patients and 7% in outpatients. 
(Schnyder & Pichler, 2009).   
 
Hypersensitivity events (HEs) are types of adverse drug reactions which are unpredictable and 
may not be dose related, however, these reactions are “characterized by objectively reproducible 
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symptoms and/or signs initiated by exposure to a drug at a dose tolerated by normal individuals”. 
(Giavina-Bianchi, Patil, & Banerji, 2017)  In addition, these reactions can be caused by immune 
mediated or non-immune mediated mechanisms. (Stone, Phillips, Wiese, Heddle, & Simon, 
2014)  Both types of HEs, immune and non-immune mediated, may be sudden and severe. 
(Stone, Phillips, Wiese, Heddle, & Simon, 2014),  According to Gomes et al, drug 
hypersensitivity drug events comprise approximately a third of adverse drug reactions. (Gomes 
& Demoly, 2005)  
 
Drug allergy an immune mediated hypersensitivity event, which is defined by the Joint Task 
Force as “an immunologically mediated response to a pharmaceutical and/or formulation 
(excipient) agent in a sensitized person.” (Drug Allergy: An Updated Practice Parameter, 2010)  
A severe potentially life-threatening form of drug allergy is referred to as an anaphylactic 
reaction or anaphylaxis.  This is in contrast to pseudo-allergic reactions, which are often referred 
to as “anaphylactoid reactions” and are not caused by IgE-mediated immune mechanisms. (Drug 
Allergy: An Updated Practice Parameter, 2010)   In 2018, the World Allergy Organization 
recommended these types of reactions be referred to as “nonimmune anaphylaxis”.  It may seem 
contradictory to categorize these reactions in the “immune disorder” category in the adverse 
events tables, however, these reactions do involve immune related mechanisms such as mast 
cells (which release histamine) and basophils without an “immune complex formation” 
(antibody-antigen complex). (World Allergy Organization, 2018)  Severe hypersensitivity 
reactions are commonly associated with cancer therapeutic agents such as monoclonal antibodies 
and chemotherapeutic agents as well as contrast agents. (World Allergy Organization, 2018)   
Figure 1 below displays the hierarchy of adverse drug events. 
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Anaphylactic type Reactions 
The sudden and severe form of an allergic reaction is often referred to as anaphylaxis. (Stone, 
Phillips, Wiese, Heddle, & Simon, 2014)  Although, this term had been previously poorly 
defined prior to 2010 and continues to be debated in some allergy circles.  The definitions used 
to describe anaphylaxis include the words “serious” and “rapid onset” and often refer to the 
potential of shock and death as an outcomes. (American Academy of Allergy, Asthma & 
Immunology, 2020) (Simons, Ardusso, Bilo, Bilio, & et al., 2011). (National Cancer Institute, 
2020)  The World Allergy Organization guidelines published in 2011 lists the criteria for a 
“highly likely” diagnosis of anaphylaxis based on the timing of the onset of symptoms (sudden), 
the types of symptoms involved in the reaction, and whether or not the patient has been exposed 
to a “known allergen”. (Simons, Ardusso, Bilo, Bilio, & et al., 2011)  The generally accepted 
symptoms of this severe adverse event include: rash, wheezing, stridor, difficulty breathing, 
syncope, abdominal systems, and oral pharyngeal edema (swelling). (American Academy of 
Allergy, Asthma & Immunology, 2020) (Simons, Ardusso, Bilo, Bilio, & et al., 2011)  The NCI 
Thesaurus definition also notes the physiology of the reaction in which histamine release occurs 
in response to allergen exposure.  The term is listed as a lower level term (LLT) and as a disease 
or syndrome semantic type. (National Cancer Institute, 2020) 
 
Anaphylaxis is increasing in incidence, currently thought to be approximately 4-50/100,000 
person-years (Kim et al, 2014).  Additionally, hospital admissions with a diagnosis of 
anaphylaxis have been increasing in number (Turner et al, 2015), which likely indicates 
increasing incidence of severe allergic reactions or could be due to improved reporting. Accuracy 
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and standardized reporting of HEs, especially immediate allergic, events in cancer clinical trials, 
allows for population level studies of the potential risk factors for these events.  Population level 
studies, e.g. studies conducted using population-level healthcare databases, can improve the 
power of studies, especially in cases of rare forms of cancer or studies which may have low 
enrollment.   Analysis of the potential risk factors involved in HEs aids in development of 









































Hypersensitivity events in clinical cancer therapy 
In addition to the increase in incidence of cancer in the population as discussed above, there is 
also a projected further increase in new cancer diagnoses of approximately 70% within the next 
twenty years. (Giavina-Bianchi, Patil, & Banerji, 2017) Several new therapies are developed 
each year.  Therefore, the risk of hypersensitivity events during cancer treatment, with the use of 
chemotherapy and biological agents, will likely increase.  In fact, a study of mortality data from 
the U.S. National Center for Health Statistics (NCHS) determined anti-neoplastic agents (cancer 
medications) as the third most common cause of fatal drug induced anaphylaxis. (Jerschow, Lin, 
Scaperotti, & McGinn, 2014)  
 
Cancer Diagnostic and Therapeutic Agents 
Cancer drugs and biological agents are commonly used in cancer treatment, and most of these 
drugs and agents have been associated with hypersensitivity events. (Lee, Gianos, & 
Klaustermeyer, 2009).  Cancer therapy can be divided into several types of treatments which, 
according to the NCI, include the following: chemotherapy, immunotherapy, hormone therapy, 
radiation, targeted therapy, stem cell transplants, precision medicine and surgical treatments.  
This study will focus on chemotherapy (drug therapy) and immunotherapy (biological therapy).  
Immunotherapy can be used in precision medicine and target therapy. (NCI, 2015)  
 
Several studies have noted the presence of hypersensitivity events to chemotherapy agents such 
as the platinum class of drugs which includes carboplatin.  In the case of platinum agents, the 
adverse hypersensitivity events can be dose dependent, in contrast to taxanes and monoclonal 
antibodies which generally occur during the first or second infusion. (Lenz, 2007) Therefore, 
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research on predictors associated with the class of drug in an intervention can have a significant 
impact on the need for preparation and prevention of severe hypersensitivity events. 
 
Biological therapies:  Immunotherapy and targeted therapies 
Biological agents differ from chemotherapy as these agents are derived from living organism or 
the substances are created in a laboratory to resemble the natural substances and used to 
eliminate cancer cells during therapy. (Dana-Farber Cancer Institute, 2017)  According to the 
NCI, there are several types of biological therapies which are used to treat cancer, which are 
generally divided into the following categories by the NCI:  Immune checkpoint inhibitors, 
immune cell therapy, therapeutic antibodies, therapeutic vaccines, and immune-modulating 
agents (NCI, 2018)  Biological agents are associated with severe hypersensitivity infusion 
reactions and these reactions can be fatal. 
 
Immunotherapy, which is a type of biological therapy, approaches the treatment of cancer from a 
different mechanism of action than chemotherapy.  Immunotherapy works via either attacking 
the cancer cells or by mechanisms which stimulate the patient’s own immune system to aid in 
targeting the cancer cells within the patient’s body (NCI, 2018) (Dana-Farber Cancer Institute, 
2017)  Therapeutic antibodies are an example of a type of targeted cancer therapy, which are 
created in a laboratory to bind to cancer molecules to block the replication of cancer cells in the 





Chemotherapy and Hypersensitivity Reactions 
In contrast to biological therapies, chemotherapies have been the mainstay of cancer therapy for 
decades.  These agents treat cancer by interfering with the cancer cell’s ability to divide, 
therefore, inhibiting cancer growth.  Unfortunately, these drugs have several adverse effects and 
can also affect the growth of normal cells, a common manifestation of this is hair loss.  In 
addition, certain classes of chemotherapeutic drugs are frequently associated with adverse 
hypersenstivitiy events, and as noted above, some may correlated with the number of drug 
infusions.  However, in certain drug classes, de-sensitization methods may be used prior to 
administration to the patient to minimize these adverse hypersenstivity events in at-risk patients. 
(Guitart, 2014)  Therefore, using data-driven approaches to study clinical trial data can 
potentially aid in identifying the most likely etiologic agents and the patients at most risk of a life 
threatening response to drug administration. 
 
Cytokine release syndrome 
A severe adverse immune response associated with biological and chemical agents, e.g. 
monoclonal antibody (mAB) therapy, for cancer patients is cytokine release syndrome (CRS).  
This is an adverse immune event caused by the sudden release of immune substances referred to 
as “cytokines” from cells targeted and/or affected by the antibody therapy which result in several 
symptoms described in figure 2 below.  However, the exact mechanism of how this occurs is not 
yet completely understood. (Shimabukuro-Vornhagen, et al., 2018)  CRS may in some instances 
be referred to as an “infusion reaction” and can vary in severity from mild to severe (life 
threatening immune events). (Breslin, 2007)  According to the NCI, most of these events are 
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mild to moderate in severity, however, some events can be life-threatening. (National Cancer 
Institute, n.d.) 
 
Figure 2.  Etiology and Symptoms of Cytokine Release Syndrome 
 
 
An important point to highlight here is the similarities in terminology descriptive needs between 
CRS and anaphylactic events.  Both events may vary in severity and have been associated 
directly with specific allergens.  Additionally, both events have several symptoms which may be 




Brief History of ClinicalTrials.gov 
 
The Food and Drug Administration Modernization Act of 1997 (FDAMA) included a section 
requiring the National Institute of Health to create a public registry of clinical trials, specifically 
trials which involved drugs treating life-threatening health conditions (U.S. National LIbrary of 
Medicine ClinicalTrials.gov, 2018). The legislation is intended to improve public access to 
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health information on clinical trials of experimental therapies.  In 2000, the ClinicalTrials.gov 
website was launched. (Press Release: National Institutes of Helath Launches 
"ClinicalTrials.gov", 2000)  In 2005, further legislation was published by the International 
committee of Medial Journal Editors to require trial registration “as a condition of publication”. 
(ClinicalTrials.gov, 2018)  The following year, the World Health Organization (WHO) 
recommended that all clinical trials be registered.  WHO created their own platform, which 
incorporates data from ClinicalTrials.gov. (World Health Organization, 2019) 
In 2007, Public Law 110-85 Sec. 801, “Expanded Clinical Trial Registry Data Bank”, was 
passed by Congress requiring expansion of the current data entry requirements for this clinical 
trial registry and public online access.  Required reporting included:  clinical trial title, summary, 
study type and design, primary and secondary outcomes, demographic data, dates. (Congress, 
2007)   In 2009, sponsors of clinical trials were required to enter adverse event reports into 
ClinicalTrials.gov. (Neuer, 2009) 
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Cancer Adverse Event Reporting in ClinicalTrails.gov 
Clinicaltrials.gov uses the following definition for adverse events: 
Any untoward or unfavorable medical occurrence in a participant, including any 
abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or 
disease, temporally associated with the participant’s participation in the research, whether 
or not considered related to the participant’s participation in the research. 
(ClinicalTrials.gov, 2018) 
 
Adverse event types recorded in Clinicaltrails.gov are entered into the following three adverse 
event tables by the clinical trial investigator:  All-cause mortality; Serious adverse events (AEs); 
Other (Not Including Serious) AE .  (ClinicalTrials.gov, 2018) 
  
In clinicaltrials.gov, adverse event reporting is not required to follow a specific standard 
terminology or classification system.  Rather, adverse event data is entered into the three tables 
using the investigators standard vocabulary or classification system of choice.  However, there is 
a requirement for investigators to enter adverse event reporting into semi-structured tables which 
follow an organ system category approach used by the Medication Dictionary for Regulatory 
Activities (MedDRA). (Goss, et al., 2013)    
 
Adverse event data elements include the following:  Time frame, description, source vocabulary 
name, collection approach (systematic vs. non-systematic), total number affected, total number at 
risk, and organ system.  Investigators submit this data into semi-structured “Serious Adverse 
Event” and “Other (Not Including Serious)” tables organized by organ systems.  Please see the 






Figure 4. Screenshot of Other (Not Including Serious) Adverse Events Table 
 
(U.S. National Library of Medicine, 2017) 
ClinicalTrails.gov data element definitions are listed on their website and can be retrieved at: 
https://prsinfo.clinicaltrials.gov/results_definitions.html#AdverseEvents   
Currently, the National Library of Medicine has begun an effort to “modernize” this website and 
database in order to improve its usability for investigators, patients, family members and 
researchers who use this data for secondary population level research. (U.S. National LIbrary of 




Medical Terminologies for Adverse Drug Reporting 
In the 1990’s, the need for more standardized reporting of clinical trial outcomes and adverse 
events was evident to researchers and journal editors who responded to this need with the 
Consolidated Standards of Reporting Trials (CONSORT) statement. (Peron J, 2012)  The 
specialized need for improvement in the comprehensiveness and quality of reporting of adverse 
events and outcomes in randomized controlled trials, especially in cancer clinical trials where 
potential drug toxicities and narrow therapeutic indexes are common, was apparent. (Ghimire S, 
2014) 
 
To address this gap in standardized clinical trial reporting, the National Cancer Institute 
developed a controlled classification system specifically to record adverse events in clinical 
cancer trials called Common Toxicity Criteria (CTC) created in 1983, and updated with a version 
2 prior to the change in name. (Trotti, et al., 2003)  In 2006, the Common Terminology for 
Adverse Events or CTCAE version 3.0 was published, CTC was rename CTCAE removing 
“toxicity” from its name. (Trotti, et al., 2003)  This terminology is organized according to the 
MedDRA system organ class. Adverse events each have a specific definition and the events are 
graded based on severity criteria.  The latest version for cancer adverse reactions mapping 
(version 5) is current available on the National Cancer Institute website (NCI).  According to the 
CTCAE quick reference guide, CTCAE version 5 not only uses the same system organ 
classification as MedDRA, this version has also incorporated elements of MedDRA’s 




Common Terminology Criteria for Adverse Events in Cancer Clinical Trials 
The Common Terminology Criteria for Adverse Events (CTCAE) was developed by the 
National Cancer Institute to record common adverse events in clinical cancer trials.  The use of 
this classification system is required for recording adverse events in any NCI funded clinical 
cancer research study.  The CTCAE classification system consists of twenty-eight categories of 
adverse events groups by MedDRA’s System Organ Class (SOC).  Each of these SOC, include 
relative adverse events to the SOC and each adverse event uses grading scales based on clinical 
criteria which include symptoms, signs, vitals and laboratory to classify severity. (National 
Cancer Institute, 2020) (Richesson, Fung, & Krischer, 2008)  The general guideline for grade 
levels of severity in CTCAE is shown in Figure 3 below, however, the criteria to meet each level 
is specific for the adverse event shown using anaphylaxis as an example in Table 2 below.   In 
order for an event to be included in a severity level, the clinical trial participant experiencing the 
event should exhibit one or more of the criteria included in that grade.  Therefore, it is difficult to 
assess which of these criteria were present and which criteria were not present in the particular 
grade level to classify the adverse event in grades 1-5.  When performing large population level 
studies using big data from sites such as ClinicalTrials.gov, investigators are unable to determine 
the sign or symptom specifically, only the severity grade.  If evidence-based medicine and 
clinical research in subsequent versions of CTCAE lead to updates in the criteria necessary meet 
the standard for the severity level for a particular disease or condition, the ability to aggregate 
grade levels could be affected and the inclusion of the events from prior years in longitudinal 
studies would require some level of mapping between the versions. (Richesson, Fung, & 
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Krischer, 2008)  Therefore, improving the granularity of the terms would improve data aggregate 
quality. 
 
Prior to the development of CTCAE, the NCI used the Common Toxicity Criteria (CTC) which 
was developed in 1994 with version one and last updated in 2017 with version five. (EORTC, 
n.d.)  The two types of classification systems overlapped in use for some time, however, CTCAE 
is currently more the preferred classification system used by the NCI.  Both classification 
systems are listed under the Cancer Therapy Evaluation Program, however, CTC has been 
archived. (National Cancer Institute, 2020) 
 
Table 1.  CTCAE Grading Scale for Severity of Adverse Events 
Grade Severity Level Description 
1 Mild Asymptomatic or mild 
symptoms, no intervention 
2 Moderate Minimal or non-invasive 
intervention indicated; 
limits instrumental ADLs 




4 Life-threatening Urgent intervention 
indicated 
5 Death Death related to AE 
Reference:  Adapted from “Common Terminology Criteria for Adverse Events v4.0 (CTCAE) 
(U.S. Department of Health and Human Services, 2008) 
 
 
Unfortunately, a cancer trial study using data from the years 2012-2013 revealed that categories 
used to encode AEs and grade levels were often incorrectly coded. (Zhang, Liang, & Tannock, 
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Use and misuse of common terminology criteria for adverse events in cancer clinical trials, 
2016) (Zhang, Chen, & Wang, The use of and adherence to CTCAE v3.0 in cancer clinical trial 
publications, 2016)  Currently, CTCAE version 5 is available for download at the NIH National 
Cancer Institute website. (National Cancer Institute, 2018)  To our knowledge, no further study 
of later CTCAE versions has been published.   
 
CTCAE, in contrast to MedDRA, possesses the ability to code an “allergic reaction” at all five 
grades, however, there is no ability to code “anaphylaxis” at the lower severity grading levels 
(one and two) due to the severity of this particular condition.  In CTCAE and SNOMEDCT_US, 
the preferred term (PT) is “Anaphylaxis”, in comparison to MedDRA in which the PT is 
“Anaphylactic reaction”. (National Cancer Institute, n.d.)  Other synonyms to this term are acute 
anaphylaxis, acute anaphylactic reaction, generalized anaphylaxis, systemic anaphylactic 
reaction, and systemic anaphylaxis.  The term “anaphylactic shock” is also used which indicates 
signs and symptoms of shock, such as decreased blood flow, loss of consciousness and/or 
hypoxia, were present as one or more of the symptoms. (National Cancer Institute, n.d.)  Please 
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Hypotension 
managed with one 
pressor; hypoxia 












* If related to infusion, use Injury, poisoning and procedural complications: Infusion related 
reaction. Do not report both. 
 
Reference:  Adaptive from the NCI CTEP Cancer Therapy Evaluation Program CTCAE v5.0 
Quick Reference 5 x 7. (U.S. Department of Health and Human Services, 2017) 
 
MedDRA and its relationship to CTCAE 
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According the National Cancer Institute website’s NCI Term Browser, CTCAE is “harmonized 
with MedDRA at the Adverse Event (AE) level.” (National Cancer Institute, 2020)  CTCAE 
draws from the high-level terms used by MedDRA’s System Organ Class (SOC) hierarchy as it 
uses the same body system level classification of adverse events, e.g. immune system disorders 
is the category used to classify hypersensitivity events.  In contrast, MedDRA does not assign 
each adverse event term a grade level based on severity. (U.S. Department of Health and Human 
Services, November)  Mappings of each version of CTC or CTCAE to MedDRA are available on 
the NCI website. (National Cancer Institute, 2018) 
 
Lack of consistent use of controlled terminology 
“Large data sets are hindered by lack of robust utilised coding systems, with underreporting, 
miscoding and many cases of “unspecified” triggers in admissions and fatality registers” (Turner 
& Campbell, 2017)   Lack of standards in the terms used to describe anaphylaxis and collection 
methods remains a challenge to studying this type of severe adverse event on a population level 
in large databases, however, this type of study has not been conducted in clinical trial data to our 
knowledge. (Turner & Campbell, 2017) Effective use of terminologies and/or classification 
systems to represent anaphylactic and anaphylactoid events could begin to address this 
challenge, however, to compound the problem, Clinicaltrials.gov allows for any type of standard 
terminology or classification system to allow for investigator flexibility when entering the 
adverse events into the three AE summary tables:  All-Cause Mortality, Serious Adverse Events 
and Other (Not including Serious) Adverse Events.  Additionally, there is no requirement to 
specify which type of terminology or classification system was used. (ClinicalTrials.gov, 2018) 
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Variation in Adverse Event Clinical Trial Collection Methods 
Time frame, AE description, source vocabulary, and collection approach are also recorded by the 
investigator.  Again, investigators are not mandated to use a particular type of adverse event 
collection method or terminology/classification system, rather, they are instructed to add the 
information on the method and system into the adverse event table and this is latter added as a 
footnote after each term (see figure 5 below in Chapter 3.  Methods).  The permissable values for 
collection methods reported may be either systematic assessment, non-systematic assessment or 
not specified.  Systematic assessment as a data collection is defined by ClinicalTrials.gov as a 
consistent method (e.g. protocol, questionnaire, diary, etc.) of routinely assessing clinical trial 
participants for adverse events either during visits or using reporting tools, in contrast to their 
definition of a non-systematic assessment method which relies primarily on patient self-reporting 
and “unsolicited” with no formal methods or protocol of collecting adverse events. 
(ClinicalTrials.gov, 2018)  (U.S. National Library of Medicine, 2017) 
 
 Challenges in allergy documentation in EHRs as noted by Goss et al in their study of the 
comprehensiveness of standard terminologies to capture allergy, a type of hypersensitivity 
reaction.  Only SNOMED CT was able to document lack of allergies (e.g. NKDA) as of the 2013 
article publication date.  Additionally, the authors found RxNorm better for drug related allergies 
and UNII for food and substance allergens.  The investigators note MedDRA “lacks formal 
definitions to relate manifestation to causative agent or severity” and “excludes information on 
drug/product terminology” which explains why the use of the RxNorm terminology system 
maybe a better choice in the case of drug hypersensitivity events. (Goss, et al., 2013)  This is 
concerning given that MedDRA is one of the most common terminology types used in 
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ClinicalTrials.gov and the basis for the categorization of the adverse event tables. Perhaps, this is 
due to the easy of entering the data into the same organ system categories. 
 
Previous Work on Evaluation of the Comprehensiveness of Terminologies in Hypersensitivity 
Reporting of allergic events 
  
Goss et al. evaluated the encoding of allergy by comparing SNOMED CT, NDF-RT, RxNorm, 
UNII, and MedDRA.  The group analyzed each of these controlled terminologies and how they 
compared to each other with regards to their content coverage and ability to encode both the 
reaction and the etiologic agent when encoding allergy events in electronic health records.  
SNOMED CT was found to be the most comprehensive standard terminology (also uses post-
coordination), however, RxNorm was noted to be a good method to encode drug allergens.  The 
authors state the challenges unique to encoding allergic reactions which include the need to code 
the etiologic allergen, the symptoms/signs, the severity of the event and the addition of negative 
findings (e.g. no known drug allergies or no known allergies).  (Goss, et al., 2013)  
 
Furthermore, different versions of the same controlled terminology or classification system can 
drastically change the ability of the terminology or system to capture adverse events.  For 
example, a study of the incidence of adverse events in Bevacizumab therapy in patients being 
treated for glioma using different versions of CTCAE (3.0 & 4.0) noted a large difference in the 
incidence of severe hypertensive events.  CTCAE version 3.0 reported 9.5% vs. 45.2% in version 
4.0.  (Bumes, et al., 2016)   This is likely due to a change in criteria to meet the severe level of 
this category. 
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CHAPTER THREE:  METHODS 
 




The data used in this study was obtained from ClinicalTrials.gov (discussed above).  Semi-
structured adverse event tables are available for secondary study of clinical trial data.  The data 
used was collected from September 20, 1999 to March 2018. 
The full dataset from clinicaltrial.gov  was obtained in March 2018. After retrieving 255,065 
datasets, filters were used to find clinical trials with recorded hypersensitivity events. 
Please see below for the set of filters: 
allTrials = get_trials_from_source('clinicaltrial.gov’)    # get all clinical trials 
from the website 
filter.filter_trials_by_valid_clinical_results(allTrials)   # only selecting clinical 
trials with valid adverse event/Other event results 
filter.filter_by_category(categoryName = 'Immune system disorders’) # only 
select the section named "immune system disorders” in adverse event reports 
filter.filter_by_drug_list(drugList= drugSource.DrugList) # only select trials that 
use at least one of drugs in specified drug list" 
filter.filter_by_condition(conditionName = cancer_terms)  # the overall report 
must contain at least one cancer terms from the cancer-terms list 
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Original dataset was created using NLP methods.  An XML parser was created to extract 
readable text data from adverse event tables from ClinicalTrails.gov. 
 
Steps to create the drug and biological intervention terms list 
1. An initial query of the data from ClinicalTrials.gov was queried was performed in 
2016 to extract HEs using the following terms:  Hypersensitivity, allergic 
reaction, allergy, anaphylaxis, dermatitis allergic, drug hypersensitivity and 
infusion reaction.  After the results were reviewed, the query was expanded to 
include broader category of “immune disorder”.  A cancer intervention drug list 
was created from the clinical trial intervention variable using a data driven 
approach.  (see Figure 2 below) 
2. Frequency analysis of the intervention words in the clinical trial intervention 
section was performed to identify the most commonly used intervention words 
using for describing drug interventions 
3. Words were analyzed manually and incomplete or non-intervention words were 
removed. (e.g. “Na+” or “and”).  The list of removed terms was archived as a 
reference baseline.  
4. An Oncology Fellow reviewed and removed non-chemotherapy agents or 
chemotherapy agents that are not currently used in cancer therapy 
5. Duplicate interventions were removed. 
6. Cancer drugs were classified by drug class in consultation with the Oncology 
Fellow 
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7. Cancer trial interventions were then split into two broad groups:  Single therapies 
and Combination drug therapies. 
8. Another query for hypersensitivity reactions was performed using a join with this 
newly created common cancer drug intervention term list to search the original 
database of clinical trial adverse reactions (#1) again (iterative process). 
See Appendix A for complete list of drugs and biological agents. 
 






Part 1a:  Data Quality Analysis 
 
1. Data was analyzed for spelling errors and use of abbreviations.  This were 
corrected. 
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2. NCI trial arms were reviewed while recording terminology types manually, 
randomly selected clinical trials were verified by returning to the original data in 
ClinicalTrials.gov to test for accuracy of numbers of affected and at risk clinical 
trial participants. 
3. NLP data extraction errors were returned to the lab for analysis and correction of 
the data pipeline and NLP methods. 
4. After data corrections, random records were again selected for a final data quality 
check. 
 
Part 2:  Descriptive analysis of the dataset and creation of a subset of severe 
events  
 
The dataset was analyzed descriptively to provide a population level view of the characteristics 
of immune disorder hypersensitivity events in cancer clinical trials:  Cancer types, drug 
interventions, number of participants affected, number of participants at risk, number of serious 
events and number of other (not including serious events).   
 
Additionally, severe anaphylactic, anaphylactoid and grade 3-5 hypersensitivity adverse events 
were identified as a subset of the original dataset.  This subset of severe events was analyzed 
using pivot tables in Excel.  A pivot table of the data points “adverse event” and “sum of affected 
number” and “sum of at-risk number” in each clinical trial arm was created.  Furthermore, 
another pivot table was created with the severe anaphylactic type events along with the severity 
level for each event, number of clinical trial arms, number of affected participants and number of 
at-risk participants.  CRS events were not included in this subset as it was not possible to 
determine if the events were severe due to the lack of grading of these events. 
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Part 3.  Terminology evaluation  
  
 
The subset of severe anaphylactic and anaphylactoid type adverse events was analyzed to 
determine the type of controlled terminology or classification system used to record each of these 
adverse events.  Unfortunately, this data point was not discretely recorded in the adverse event 
tables within ClinicalTrials.gov.  Instead, the terminology or classification system for each 
clinical trial was reported as a footnote at the bottom of each adverse event table, the table for 
serious events and the table for other (not including serious) events.  Please see the screenshot 
below in Figure 6 below.  Therefore, manual data extraction of these data points was required. 
 
The two data points, controlled terminology/classification system and adverse event data 
collection methods, were entered into two newly created columned in the Excel spreadsheet for 
analysis.  In addition, the date of the first result entry and the date of last result update for each 
clinical trial arm was recorded in two more discrete data columns within the spreadsheet.  Pivot 
tables were created to analyze clinical trial investigator choice of controlled 
terminology/classification system for each term which representing a severe hypersensitivity 
adverse event.  Then, descriptive analysis was performed to determine the total number of 
different terminology and classification system types used to describe these events.  Also, the 
total number of clinical trial participant adverse events and the total number of at-risk clinical 
trial participants was determined for each adverse event term and terminology/classification 
system in the severe hypersensitivity data subset. 
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In cases where there were no superscript or footnotes, the clinical terminology and collection 
method was recorded as “not specified”.  Using the date of first recorded result, tables of 
terminology/classification systems by initial year of use and date ranges of 
terminology/classification system use was created.  Additionally, the number and types of 
versions of each system was determined. 
 
Figure 6.  Screen Shot of Clinical Trial Adverse Event Results with Controlled 
Terminology Type and Collection Method 










Part 4:  Methods used to test each hypothesis 
 
Hypothesis #1:   
The ability to accurately document severity of hypersensitivity events secondary to cancer 
biological or chemotherapy agents is improving with the use of the CTCAE classification system 
and its emphasis on severity levels in comparison to MedDRA.  
 
Test of presence of severity grade 
To test the hypothesis that the CTCAE classification system has improved the ability of clinical 
investigators to capture the severity of severe anaphylactic and anaphylactoid events in clinical 
cancer trials in comparison to MedDRA, first the terms used to describe these events in both 
systems were analyzed and categorized in to groups based on the type of terminology used to 
describe the event and whether a grade level was included, for example CTCAE terms with a 
grade, CTCAE with no grade, MedDRA terms with a grade, MedDRA terms with no grade, 
terms with no specified terminology with a grade etc.  MedDRA is expected to not include grade 
levels, therefore, CTCAE should in theory, perform better in capturing hypersensitivity event 
severity.  Second, due to low cell levels of less than 5, a Fisher’s exact test was used to test the 
statistical difference between categories.  The category of cytokine release syndrome/infusion 
reaction events was analyzed separately as these are categorized differently in CTCAE as 





Test of accuracy of hypersensitivity adverse event severity 
The data subset of severe anaphylactic and anaphylactoid adverse events was categorized into 
two subgroups:  Serious events and other (not including serious) events.  Anaphylactic and 
anaphylactoid types events are by definition severe and as discussed in Chapter 2, the 
classification system for CTCAE does not allow for coding of these events at grades lower than 
three (severe).  Therefore, adverse events reported by clinical trial investigators as “other (not 
including serious)” have not accurately recorded the severity level of the anaphylactic or 
anaphylactoid adverse event. 
 
To test the hypothesis of whether the NCI CTCAE classification system with its emphasis on 
severity grade levels (one through five) is improving the ability to accurately record 
hypersensitivity event severity, the most common terms from the severe data subset were divided 
into four subgroups:  anaphylactic events labeled serious using the MedDRA term “anaphylactic 
reaction”;  anaphylactic events mislabeled as other using the MedDRA term “anaphylactic 
reaction”;  anaphylactic events labeled serious using the CTCAE term “anaphylaxis” or 
“anaphylaxis to X” or “X anaphylaxis” where X is equivalent to the antigen; and anaphylactic 
events mislabeled other using the CTCAE term “anaphylaxis”.  Given both terms represent 
severe events, neither term should be represented in the “other (not including serious)” adverse 
event table.  In other works, the value for adverse hypersensitivity events labeled with one of 
these two terms should be labeled as serious and not labeled as other than serious as discussed in 




Table 3.  Method for comparing accuracy of severity label for severe hypersensitivity 
events 

















C + D 
Total  A + C B + D A + B + C + D 
 
The percentage of severe events coded as “other (not including serious) was determined for each 
term.  Additionally, the statistically difference between the observed events in each category was 
compared to the expected events in each category.  The expected number in each category was 
determined by multiplying the total number of events in the corresponding column by the 
corresponding row and dividing the product by the total number of events.  For example, in 
Table 3, the expected number of serious anaphylactic events mislabeled as “other than serious” 
using the MedDRA term “anaphylactic reaction” was determined by 
(B+D)*(A+B)/(A+B+C+D).  A Chi Square test was then used to determine if there was a 
significant difference between the MedDRA terms, CTC terms, CTCAE terms, and Not 
Specified terms groups. (Hall & Richardson, 2016) 
 
Hypothesis #2:  
Terms used to describe severe anaphylactic and anaphylactoid events recorded in the dataset of 
clinical cancer trials from ClinicalTrials.gov rarely (<5% of events) include the antigen 
responsible for the event which hinders the ability to study incidence of drug and biological 
agent induced hypersensitivity events when the clinical trial intervention includes multiple drugs 
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and/or multiple therapeutic agents.  In other words, there is no statistical difference between the 
types of terminologies or classification systems used regarding the inclusion of the antigen 
within the severe hypersensitivity event term. 
 
The subset of severe anaphylactic and anaphylactoid adverse events which included the terms 
anaphylaxis, anaphylactic reaction, anaphylactic shock, and grade 3 or 4 allergic or 
hypersensitivity reactions, and variations of these terms, e.g. “Bactrim anaphylaxis”, were 
categorized into groups by the type of controlled vocabulary or classification system and whether 
the term including the name of the allergen which was the etiology of the severe hypersensitivity 
event.  The categories were compared statistically with the Fisher’s exact test (due to cell 
numbers less than 5) to determine if a statistical significance exists between the terminology, 
classification system, or unspecified terminology groups with regards to the inclusion of the 
allergen.  The same method was used to analyze the cytokine release syndrome and infusion 
reaction group. 
 
Hypothesis #3:  Over 25% of the severe anaphylactic and anaphylactoid events have not been 
collected using a systematic assessment method which could result in underreporting of events. 
 
Data regarding collection approach methods were reported as a footnote below the semi-
structured adverse event tables in ClinicalTrials.gov which required manual data extraction of 
the descriptive terminology and data collection method.  Please refer to Figure 5 above.  The 
unique NCI identification number of the trial arm was used to query the database via the search 
engine found at the ClinicalTrial.gov home page.  Adverse event collection methods were 
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recorded in a separate column in the datasheet as either systematic assessment, non-systematic 
assessment or unspecified collection method which are the only permissible values in the adverse 
event tables, see Figure 4 above.  The incidence of use of a systematic assessment collection 
method was calculated for severe hypersensitivity adverse events using the most commonly 
recorded terms:  anaphylaxis, anaphylactic reaction, anaphylactic shock, and anaphylactoid 
reaction.  Each adverse event was categorized by term and collection method.  A Chi Square test 



































The final dataset of adverse immune events included 1331 NCT unique clinical trial ID numbers 
and 5595 clinical trials arms (each clinical trial may have more than one).  The results of the 
descriptive analysis of total immune system disorder events, in all clinical trials reporting 
adverse events, returned 13,088 recorded adverse immune mediated events out of 895,383 
participants at risk for an event after exposure to a clinical trial arm intervention.  These results 
indicate an overall incidence of 0.0146 or approximately 1.5% for adverse immune related 
events in this clinical cancer trial dataset over the timeframe of September 1999-March 2018. 
 
These 1331 clinical cancer trials involved 639 unique cancer condition combinations.  Some of 
the cancer conditions were included in more than one trial.  For example, one trial investigated 
interventions for B-cell lymphoma and follicular lymphoma while another trial investigated B-
cell lymphoma in addition to several other types of lymphoma such a T-cell lymphoma.  The 
most commonly reported types of cancer in the clinical trials reporting immune disorder events 
were breast cancer/neoplasms, multiple myeloma, colorectal cancer, lymphoma, leukemia and 
non-small cell lung cancer.  Some conditions were labeled only as “cancer”, “neoplasms”, “solid 
tumor” or “carcinoma” which made analyzing the cancer type difficult. 
 
The most frequently used term to describe immune disorder adverse events in clinical trial arms 
was “hypersensitivity”.  This high-level term was used in approximately 22.1% of clinical trial 
arms, nearly one quarter.  It also has the least ability to provide detail on allergen and severity.  
The next most frequently used terms to describe these events were:  allergic reaction (11.0%), 
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drug hypersensitivity (10.3%), anaphylactic reaction (5.2%), cytokine release syndrome (4.1%), 
allergic reaction/hypersensitivity (including drug fever) (3.6%), anaphylaxis (3.4%), seasonal 
allergy (3.4%), anaphylactic shock (2.1%), allergic reaction/hypersensitivity (1.8%), and allergic 
rhinitis (including sneezing, nasal stuffiness, postnasal drip) (1.9%).  The other terms were each 









Lower level terms which indicated severity or included allergen descriptors were used far less 
often.  For example, the term “allergic reaction” can be used to record a hypersensitivity event, 
however, when using the CTCAE classification system, the term should include a grade level.  In 
the 5595 clinical cancer trial arms, the terms which included a grade descriptor with the adverse 
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hypersensitivity event were infrequent.  Three clinical trial arms (0.05%) used the term “Grade 1 
Allergic reaction/hypersensitivity”, three arms used the term “Grade 1” Allergic rhinitis, and five 
arms used “Grade 3 Allergic reaction/hypersensitivity” (0.08%).  Two clinical trial arms (0.04%) 
used the term “hypersensitivity – grade 2”.  Finally, two clinical trials arms used terms which 
included grade 4 as a descriptor.  A total of 40 clinical trial arms used a hypersensitivity or 
immune disorder term with a grade level out of the total of 5595 arms in the dataset.  The 
calculated percentage of use in clinical trial arms was 0.7%. 
 
Subset of Severe Anaphylactic and Anaphylactoid Events 
A case study of severe adverse events, a subset of anaphylactic and anaphylactoid events, was 
created.  Events with the high-level term “autoimmune disorder” or “hypersensitivity” or 
“allergic reaction” were not included as it was not possible to determine if these events were of 
the anaphylactic or anaphylactoid type.  Terms included in this data subset were:  Anaphylaxis, 
anaphylactic reactions, anaphylactoid reaction, allergic reaction – anaphylactic, and grade 3-5 
allergic reactions.  Table 6 below lists the severe hypersensitivity adverse event, the number of 
affected clinical trial participants, the number of clinical trial participants at risk (exposed to the 








Table 5.  Immune Disorder Terms with Adverse Event Severity Grade 






Autoimmune disorder - grade 1 1 15 15 
Autoimmune disorder - grade 2 1 2 15 
Autoimmune disorder - grade 3 1 9 15 
Autoimmune disorder - grade 4 1 1 15 
Gr3 Neturopenia 1 2 5 
Grade 1 Allergic 
reaction/hypersensitivity 
3 70 345 
Grade 1 Allergic rhinitis 3 103 751 
Grade 1 Autoimmune reaction 2 53 668 
Grade 1 Rhinitis 4 46 353 
Grade 2 Allergic reaction 1 1 30 
Grade 2 Allergic 
reaction/hypersensitivity 
1 27 303 
Grade 2 Rhinitis 2 20 311 
Grade 3 Allergic 
reaction/hypersensitivity 
3 8 345 
Grade 3 Allergic/hypersensitivity 2 1 668 
Grade 3 Autoimmune reaction 3 6 971 
Grade 4 Allergic 
reaction/Hypersensitivity 
1 2 303 
Grade 4 Allergy-other 1 1 303 
Grade 4 Autoimmune reaction 2 4 668 
Hypersensitivity - Grade 2 2 1 38 
Hypersensitivity - Grade 3 3 3 74 
Leukopenia (Grade 1) 1 1 12 
Leukopenia (Grade 2) 1 1 12 
















allergic reaction - anaphylactic 4 47 1 
Anaphylactic reaction 153 107488 290 
Anaphylactic Reaction to Anti-Thymocyte Globulin 1 57 2 
Anaphylactic shock 58 41075 116 
Anaphylactoid reaction 9 19814 26 
Anaphylaxis 935 29087 193 
Anaphylaxtic reaction to erbitux 3 37 1 
Angioedema 1 57 1 
Bactrim anaphylaxis 1 85 2 
Cryoglobulinaemia 1 37 2 
Cytokine release syndrome 509 28793 230 
Cytokine Release Syndrome (Stem Cell Infusion) 2 6 2 
Cytokine Release Syndrome (Thymoglobulin) 1 6 2 
Cytokine release syndrome, ATG 12 17 1 
Cytokine release syndrome/acute infusion reaction 17 711 27 
Cytokine storm 1 207 1 
Death 8 66 2 
Grade 3 Allergic reaction/hypersensitivity 8 345 3 
Grade 3 Allergic/hypersensitivity 1 668 2 
Grade 4 Allergic reaction/Hypersensitivity 2 303 1 
Grade 4 Allergy-other 1 303 1 
Hypersensitivity - Grade 3 3 74 3 
Grand Total 1731 229283 909 
 
 
Description of Terminology and Classification Systems in the case study subset 
The clinical trial investigators reporting of initial years of clinical trial registration for studies 
which used CTC were from 2000-2010.  No new studies used this classification system after 
2010.  CTCv2.0 was initially used in 2000 and last used in an update in 2017.  CTCv4.0 was 
initially posted in 2003 and last used in an update in 2019.  The next most common type used 
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was the MedDRA terminology, 28 different versions were used to record these events, however, 
a MedDRA version was not listed in 39 of the anaphylactic data subset of events.  The first time 
MedDRA was used to report an event was in 2002 and the last time it was used in an update was 
2020.  The complete list of MedDRA dates by version is available in Appendix A. 
 
CTCAE versions 2.0, 3.0 and 4.0 were used in 48 of the events beginning with year 2003 
through last updates in 2019.  By version for this data subset, CTCAE 2.0 was first used in 2003 
and last used in an update in 2019; CTCAE 3.0 was first used in 2004 and last used in an update 
in 2019; CTCAE 4.0 was first used in 2003 and last used in an update in 2019.  In this data 
subset of severe anaphylactic type reactions, CTCAE 5.0 was not used at all. 
 
In the data subset of severe anaphylactic or anaphylactoid type hypersensitivity events which 
totaled 1238 adverse events out of 199,155 exposures (incidence 0.0062), the most commonly 
used terminology type was Common Toxicity Criteria (CTC).  A 704 of the events (56.9%) were 














Severity data element 
The ClinicalTrial.gov requires the investigator to enter the adverse events into one of two 
possible adverse event tables, serious or other (not including serious).  The adverse immune 
disorder events returned from a query of the dataset was divided into these two groups as 
follows: 2,409 participants experiencing a “serious” immune disorder event and 10,679 
participants experiencing an “other (not including serious)” event.  Taking the number of 
participants affected by an event in context with the number of clinical trial participants at risk 
for an event, less than 1% of clinical trial participants experienced a serious immune disorder 












































 2409  251399    0.0096 
Other 
events 
10679  643984    0.0166 
 
 
From a clinical trial arm perspective, each clinical investigator selected terms to describe the 
immune disorder adverse events which occurred in the clinical trial arms.  Each clinical trial arm 
represented a different type of clinical cancer intervention for an NCI trial identification number.  
Therefore, each clinical trial could report an adverse event incidence for multiple arms in each of 
the adverse event tables (severe or other than serious).  Additionally, a clinical trial could report 
“0” events for a particular event in a clinical trial arm. 
 
Cytokine Release Syndrome (CRS) 
A total of 542 cytokine release syndrome type adverse immune disorder events were reported in 
this dataset.  The terms used to report this type of immune related event were:  Cytokine release 
syndrome, cytokine release syndrome (stem cell infusion), cytokine release syndrome 
(thymoglobulin), cytokine release syndrome, ATG, cytokine release syndrome/acute infusion 
reaction, and cytokine storm.  The majority of these events (85%) were recorded as other than 
serious events.  However, none of the reactions included a grade level.  Although, minimal use of 
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CTCAE version 4 and no use of CTCAE version 5 (published 2017) (U.S. Department of Health 
and Human Services, 2017) was recorded and the grade levels for this condition first appeared in 
version 4.0.  Figure 7 below visualizes the percentage of CRS adverse events which were labeled 
as serious verses other events. 
 





Hypothesis #1   
The ability to accurately document severity of anaphylactic and anaphylactoid events secondary 
to cancer biological or chemotherapy agents is improving with the use of the CTCAE 








The results indicate this hypothesis is not true.  When CTCAE terminology was used to describe 
severe anaphylactic or anaphylactoid events, the CTCAE grading system was not used.  In 
addition, the severity of the preferred term in the CTCAE classification system to describe 
anaphylactic events, “anaphylaxis”, was often miscoded as “other (not including serious)” 
instead of “serious” in the data field which allows one of these two permissible values which 
corresponds to the particular adverse event table (serious or other).  
 
Severity Grading of Anaphylactic or Anaphylactoid Events 
ClinicalTrials.gov does not have a severity grading data field, instead the NCI encourages 
clinical trial investigators to report adverse clinical cancer trial events using the CTCAE 
classification system, which uses clinical symptoms and signs as criteria to determine the adverse 
event severity grades levels one through five as discussed in Chapter 2.  The grade is then 
included with the term, for example, Grade 4 Anaphylaxis. (Unified Medical Language System, 
n.d.)   The 48 severe anaphylactic and anaphylactoid adverse events reported using the CTCAE 
classification system, including versions CTCAE 2.0, CTCAE 3.0, or CTCAE 4.0, did not 
include a severity grade levels in any of the event terms.  CTC, the older version of CTCAE, also 
did not include severity grade levels in any of the 704 reported events using this classification 
system.  MedDRA did include a grade level in one of the 216 events reported using this 
terminology system.  Only six clinical trial arms were not able to be categorized into the above 
groups:  “Adeers not subm” (1); “COSTART, CTCAE v3.0” (1); “15” (1); “17” (3).  It is likely 
“15” and “17” refer to MedDRA versions, however, this cannot be certain so these were 
removed from the analysis. 
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Table 9.  Terminology or Classification System and Event Severity Grading 
Terminology or Classification System No Grade Grade Total 
CTC  704 0 704 
MedDRA 215 1 216 
CTCAE 48 0 48 
Not Specified 190 14 204 
Total 1157 15 1172 
 
Severe allergic anaphylactic type events reported with a “not specified” terminology of choice 
did include grade levels in fourteen clinical trial arms as noted in the table above.  The 
investigators in these cancer clinical trials used the terms “Grade 3 Allergic/hypersensitivity”, 
“Grade 3 Allergic reaction/hypersensitivity”, “Grade 4 Allergic reaction/Hypersensitivity” and 
“Grade 4 Allergy-other”.  Although, the type of vocabulary or classification system for these 
terms were not specified, according to the UMLS, the terms are similar to the CTCAE version 
3.0 term “Grade 3 Allergic Reaction and Hypersensitivity Including Drug Fever, CTCAE 
[A29146280/NCI_CTCAE_3/PT/C54752]” and “Grade 4 Allergic Reaction and Hypersensitivity 
Including Drug Fever, CTCAE [A29160643/NCI_CTCAE_3/PT/C54757]”  (Unified Medical 
Language System, n.d.)   
 
A Fisher’s Exact Test was used to test the statistical difference due to category totals < 5.  
Interestingly, the clinical trials which did not specify their terminology or classification system 
of choice were significantly more likely to include the grade level in comparison to the MedDRA 
terminology described events with grades levels (Fisher exact test statistic = 0.0003, p < 0.05).  
This also held true for the comparison between the “not specified” terminology events and the 
CTC classification system term events with grade levels (Fisher exact test statistic value 
<0.00001, p < 0.05).  There was no statistical different between the CTCAE classification system 
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and the “not specified” terminology events, (Fisher exact test statistic value = 0.0786, p < 0.05), 
however, it may have been secondary to a lower number of events in the CTCAE category.   
 
Table 10.  Terminology Grading       
Term No Grade Grade Totals 
CTC  704 0 704 
MedDRA 215 1 216 
CTCAE 48 0 48 
Not Specified 190 14 204 
Totals 1157 15 1172     
Fisher's Exact Tests 
   
 
No Grade Grade Marginal Row Totals 
MedDRA 215 1 216 
CTCAE 48 0 48 
Marginal Column Totals 263 1 264(Grand Total)     
The Fisher exact test statistic value is 1. The result is not significant at p < .05.     
 
No Grade Grade Marginal Row Totals 
CTCAE 48 0 48 
Not Specified 190 14 204 
Marginal Column Totals 238 14 252 (Grand Total)     
The Fisher exact test statistic value is 0.0786. The result is not significant at p < .05.     
 
No Grade Grade Marginal Row Totals 
CTC 704 0 704 
CTCAE 48 0 48 
Marginal Column Totals 752 0 752(Grand Total)     
The Fisher exact test statistic value is 1. The result is not significant at p < .05.     
 
No Grade Grade Marginal Row Totals 
MedDRA 215 1 216 
Not Specified 190 14 204 
Marginal Column Totals 405 15 420(Grand Total) 
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The Fisher exact test statistic value is 0.0003. The result is significant at p < .05.     
 
No Grade Grade Marginal Row Totals 
CTC 704 0 704 
Not Specified 190 14 204 
Marginal Column Totals 894 14 908  (Grand Total)     





Additionally, the CTCAE preferred term for anaphylactic events, “anaphylaxis”, was miscoded 
as an “other (not including serious)” event the majority of the time in the ClinicalTrials.gov 
dataset.  “Anaphylaxis” was only labeled correctly as a severe event 222/935 (23.7%) of the 
time.  This term was coded in the dataset using CTCAE in the majority of these events, that is 
the investigator indicated their controlled terminology or classification system of choice as being 
CTCAE versions 2.0, version 3.0, or version 4.0.  In contrast, the use of the MedDRA term 
“anaphylactic reaction” was miscoded far less as an “other (not including serious)” event.  This 









Table 11.  Anaphylactic Terms Miscoded as Other (Not including Serious) 
 
 
Using a chi square test, the proportion of investigator correct identification of the MedDRA term 
“anaphylactic reaction” as a severe immune disorder adverse event was compared with the 
proportion of investigator correct identification of the CTCAE term “anaphylaxis” as a severe 
immune disorder adverse event.  The results indicate that there is a significant difference in the 
correct identification of an anaphylactic event as severe when using the MedDRA term 
“Anaphylactic reaction” (92.3% correct) in comparison to using the CTCAE term “Anaphylaxis” 













Severe Label Other Label
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Table 12.  Comparison of Accuracy of Severity by Term Use 
Term Severe Other  Total P-Value 
Anaphylactic reaction 145 12 157 
 
Anaphylaxis 223 713 936 
 
Total 368 725 1093 1.8939E-63 
 
Cytokine Release Syndrome (CRS) Severity Reporting 
The severity of CRS events was coded using the permissible values, serious or other (not 
including serious).  CRS is a variable condition, therefore, CTCAE does allow grading at all five 
levels.  Therefore, it was not possible to determine if the event was correctly coded or not as a 
serious event without having direct access to the original data.  Table 13 below lists the adverse 
event terms and the proportion of severe and not severe events per term used to describe these 
adverse events. 
 
As noted above in the descriptive analysis, no severity grading levels were reported with the 
terms used to describe cytokine release syndrome or acute infusion reactions.  Although, the 
CTCAE classification has terms available to describe severity grades by symptom criteria and 
oxygen requirements, for example “Grade 3 Cytokine Release Syndrome [C4686146]”. (Unified 








Table 13.  Cytokine Release Syndrome Event Severity  
Term Serious Other  Total 
Cytokine release syndrome 78 431 509 
Cytokine release syndrome (Stem Cell Infusion) 0 2 2 
Cytokine release syndrome (Thymoglobulin) 0 1 1 
Cytokine release syndrome, ATG 0 12 12 
Cytokine release syndrome/acute infusion 
reaction 
4 13 17 
Cytokine storm 1 0 1 




Severe anaphylactic and anaphylactoid events recorded in ClinicalTrials.gov rarely (<5% of 
events) include the allergen responsible for the event which hinders the ability to study incidence 
when multiple drug or multiple therapeutic agents are used in clinical cancer trials.  In other 
words, there is no statistical difference between the most common terminologies used in this 
database regarding the inclusion of the drug allergen in the allergic event term. 
 
This hypothesis is true when analyzing the events which included the terminology or 
classification system name.  As expected, the most commonly used terminologies and 
classification systems by the investigators did not support the inclusion of a drug or biological 
allergen.   MedDRA, CTC and CTCAE did not have the ability to capture the allergen 
responsible for the event.  Only two other systems were noted Adeers and COSTART which 
were used in one arm each and also did not note allergens within the terms.   The majority of 
severe anaphylactic and anaphylactoid events were recorded by clinical investigators using CTC 
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and all of the 704 events reported with this classification system used the term was 
“anaphylaxis”.  
 
Additionally, in this subset of severe events, several of the clinical trial investigators did not 
specify the terminology or classification system used.  However, a few of the events in this “not 
specified” category included the allergen responsible for the severe allergic event (5/204).  In 
other words, the only allergens recorded in any of the severe anaphylactic and anaphylactoid 
events were the adverse events in which the terminology or classification system was not 
specified by the clinical investigator.  For example, “Bactrim anaphylaxis” was used to describe 
an anaphylactic event.  The only other terms noted to have the allergen included were 
“anaphylactic reaction to Erbitux” and “anaphylactic reaction to anti-thymocyte globulin”, as 
shown in Table 14 below. 
 
Table 14.  Inclusion of Allergen with Anaphylactic and Anaphylactoid Events 
Terminology or Classification System Allergen No Allergen Total 
CTCAE 0 48 48 
CTC  0 704 704 
MedDRA 0 216 216 




Table 15.  Fisher’s Exact Tests Comparing Allergen Inclusion 
 
Results 
    
 
Allergen No Allergen Marginal Row Totals 
CTCAE 0 48 48 
 
CTC 0 704 704 
 
Marginal Column Totals 0 752 752  (Grand Total) 
  53
     
     
Fisher exact test statistic value = 1. The result is not significant at p < .05. 
     
Results 
    
 
Allergen No Allergen Marginal Row Totals 
CTCAE 0 48 48 
 
MedDRA 0 216 216 
 
Marginal Column Totals 0 264 264  (Grand Total) 
     
     
Fisher exact test statistic value = 1. The result is not significant at p < .05. 
     
Results 
    
 
Allergen No Allergen Marginal Row Totals 
CTCAE 0 48 48 
 
Unspecified 5 199 204 
 
Marginal Column Totals 5 247 252  (Grand Total) 
     
     
The Fisher exact test statistic value = 0.5867. The result is not significant at p < .05. 
     
Results 
    
 
Allergen No Allergen Marginal Row Totals 
MedDRA 0 216 216 
 
Unspecified 5 199 204 
 
Marginal Column Totals 5 415 420  (Grand Total) 
     
     
The Fisher exact test statistic value = 0.0264. The result is significant at p < .05. 
     
 
Allergen No Allergen Marginal Row Totals 
MedDRA 0 216 216 
 
CTC 0 704 704 
 
Marginal Column Totals 0 920 920  (Grand Total) 
     
     
The Fisher exact test statistic value = 1. The result is not significant at p < .05. 
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Allergen No Allergen Marginal Row Totals 
CTC 0 704 704 
 
Not Specified 5 199 204 
 
Marginal Column Totals 5 903 908  (Grand Total) 
     
     
The Fisher exact test statistic value = 0.0006. The result is significant at p < .05. 
 
 
Table 16. Cytokine Release Syndrome Terms and Severity 
Term Serious Other Total 
Cytokine release syndrome 78 431 509 
Cytokine release syndrome (Stem Cell Infusion) 0 2 2 
Cytokine release syndrome (Thymoglobulin) 0 1 1 
Cytokine release syndrome, ATG 0 12 12 
Cytokine release syndrome/acute infusion reaction 4 13 17 
Cytokine storm 1 0 1 
Total 83 459 542 
 
Although, there seems to be a trend noting the lack of notation of an allergen with CRS severe 
events in comparison to CRS other than serious events, the statistical comparison using a 
Fisher’s exact test between the categories was not significant (p < 0.05). 
 





Total Fisher exact test 
value 
CRS Serious Events 0 83 83  
CRS Other Events 15 431 446  






Over 25% of the severe allergic events have not been recorded using a systematic assessment 
method which could result in underreporting of events. 
 
The hypothesis was found to be true as only 18% of the subset of severe anaphylactic and 
anaphylactoid events were collected using a systematic collection method.  However, this 
hypothesis is difficult to assess completely due to the large number of adverse events in the 
severe anaphylactic or anaphylactoid data subset labeled as “not specified” in the collection 
method data field.  Over 75% of the events were collected with a “not specified” method, 18% 
were collected using a systematic assessment method and 6% were collected using a non-
systematic collection method as noted in the pie graph in Figure 8 below. 
 







Systematic Assessment Method Non-Systematic Assessment Method
Not Specified
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However, the collection methods varied by terminology or classification system.  In this data 
subset, 877/937 (93.6%) events including the term “anaphylaxis” (primarily used with CTC and 
CTCAE classification systems) were collected using an unspecified collection method.  In 
contrast, only 6/157 (3.8%) of terms labeled as “anaphylactic reaction”, primarily a MedDRA 
terminology term, were collected with an unspecified collection method.  In fact, 107/157 
(68.2%) of events labeled using the term “anaphylactic reaction” were collected using a 
systematic assessment method.  However, 44/157 (28%) of the “anaphylactic reaction” events 
were collected with a non-systematic assessment method.  This remains consistent with the 
hypothesis that over 25% would be collected using a non-systematic method.  Tables 17 
visualizes the terms and their collection methods.  Table 18 below lists the exact numbers by 
term and collection assessment method. 
 
























14 5 26 1
877
0
Systematic Assessment Non-Systematic Assessment Not Specified
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Table 19.  Severe Anaphylactic Type Adverse Events by Collection Methods Categories 






Not Specified Total 
Anaphylactic reaction 107 44 6 157 
Anaphylactic shock 43 14 1 58 
Anaphylaxis 55 5 877 937 
Anaphylactoid reaction 7 2 0 9 
Total 212 65 884 1161 
 
A Chi Square test was used to analyze if there is a significant difference between the categories 
of collection method (systematic assessment, non-systematic assessment or not specified) and 
investigator selected term of choice.  There was a significant difference in assessment methods 
when all categories were tested, including not specified was tested (p value < 0.05) shown in 
Table 19 below.   When just testing for a significant difference between the terms and 
assessment method categories without the “unspecified” category, the p value remained 
significant at 0.0012 shown in Table 20 below.  
 
Table 20.  Chi Square Test of Collection Method and Term Categories 
  
Chi Square 





Not Specified Total 
Anaphylactic reaction 107 44 6 157 
Anaphylactic shock 43 14 1 58 
Anaphylaxis 55 5 877 937 
Anaphylactoid 
reaction 
7 2 0 9 
Total 212 65 884 1161 
P-value 1.4816E-175 
   






Not Specified Total 
Anaphylactic reaction 28.66838932 8.789836348 119.5417743 157 
Anaphylactic shock 10.59086994 3.247200689 44.16192937 58 
Anaphylaxis 171.0973299 52.45908699 713.4435831 937 
Anaphylactoid 
reaction 
1.643410853 0.503875969 6.852713178 9 
Total 212 65 884 1161 
 
 
Table 21.  Chi Square Test of Collection Method and Terminology Categories without 
Unspecified Values 
 









107 44 151 
Anaphylactic shock 43 14 57 
Anaphylaxis 55 5 60 
Anaphylactoid 
reaction 
7 2 9 
Totals 212 65 277 
P-value 0.001222425 
  






115.566787 35.433213 151 
Anaphylactic shock 43.62454874 13.37545126 57 
Anaphylaxis 45.92057762 14.07942238 60 
Anaphylactoid 
reaction 
6.888086643 9 9 




Figure 9 uses a pie graph to visualize the large number of anaphylactic and anaphylactoid events 
in which the clinical investigator did not specify their collection method as either systematic or 
non-systematic.  Figure 10 displays the information in a pie graph using only the specified 
collection methods. 




Figure 10.  Pie Graph Displaying Anaphylactic and Anaphylactoid Adverse Event 
Collection Method without Not Specified Category 
 
 
Collection Method Including Not 
Specified Category
















Chapter V. Discussion 
 
Cancer clinical trials involve complex treatment interventions and often these interventions 
involve a combination of both biologic therapies (monoclonal antibodies) and chemotherapies.  
Monitoring adverse events involving new cancer therapies is important for patient safety 
especially potentially life-threatening hypersensitivity reactions.  Population level research can 
aid in providing frontline health providers such as physicians, nurses, and physician assistants 
with knowledge of potential predictors and risk factors for severe hypersensitivity reactions 
which can improve clinical cancer therapy and provide at-risk patients with screening and 
desensitization therapies if necessary to maintain first line therapies for cancer treatment.  
Furthermore, population level research can increase the power of studies of rare disease with 
meta-analysis methods.  The adverse hypersensitivity event data from these trials can improve 
emergency preparedness for life-threatening infusion reactions (cytokine release syndrome), 
anaphylactic or anaphylactoid reactions.  Unfortunately, the current process for collecting and 
recording the characteristics of these types of events is fault with poor granularity, inaccuracies 
in severity, missing information, controlled terminology challenges and inconsistent collection 
methods. 
 
The findings of this study indicate that several gaps exist in reporting of cancer clinical trial 
hypersensitivity events, especially severe anaphylactic and anaphylactoid events.  The specific 
areas of concern in clinical trial severe hypersensitivity event reporting were the accuracy of 
reporting the hypersensitivity event severity when using the CTCAE preferred term 
“anaphylaxis”, the lack of investigator use of the CTCAE severity grading system, and the lack 
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of ability to capture the drug allergen responsible for the severe anaphylactic, anaphylactoid or 
CRS related adverse events in multi-drug therapies.  Furthermore, a large portion of clinical 
cancer trials either did not report their adverse event collection method or do not use a systematic 




An overall analysis of the terms used in clinical trial reporting of immune disorder adverse 
events indicates the most common term used to describe cancer immune disorder adverse events 
was “hypersensitivity”.  This term was used to describe 22.2% of the immune adverse events 
over the nine year study period in which the data in this dataset was entered into 
ClinicalTrials.gov.  Hypersensitivity is a high-level term which lacks necessary descriptors to 
perform adequate pharmacovigilance of drug or biological agent monitoring of immune disorder 
events during clinical trials.  The term does indicate the event severity or whether the event was 
allergic or non-IgE in pathophysiology.  Furthermore, this term does indicate the etiology or 
allergen responsible for the hypersensitivity event occurring while the patient is receiving a 
clinical trial intervention which often involve multiple drugs, biological agents and/or other 
therapies such as radiation and surgery.  In other words, without any further information, this 
term alone will not aid in surveillance of drug or biological agent adverse hypersensitivity events 
in clinical cancer trials.  It may be the information which may have existed in the original 
investigator data has not been adequately transferred to the ClinicalTrials.gov database and 
therefore, not available to health consumers who may be searching for a potential clinical trial to 




The ability to accurately document severity of anaphylactic and anaphylactoid events secondary 
to cancer biological or chemotherapy agents is improving with the use of the CTCAE 
classification system and its emphasis on grade levels (1-5) in comparison to MedDRA. 
 
The results of the data analysis for hypothesis one indicates the use of the NCI CTCAE 
classification system has not improved the ability to capture severity and has resulted in further 
challenges in reporting severity level accuracy of anaphylactic events in clinical cancer trials.  
This is indicated by the lack of clinical investigator use of the classification system’s grades to 
capture the severity of these types of adverse events even with these terms available in the 
CTCAE versions used in these clinical trials.  In summary, clinical cancer trial investigators used 
CTCAE terms which did not include the severity grading levels to describe these severe 
anaphylactic and anaphylactoid adverse events.  For example, an investigator may report 
“Anaphylaxis, CTCAE [A29138945]” instead of “Grade 4 Anaphylaxis [A29149366]”. 
(National Cancer Institute, n.d.) 
   
Furthermore, the results indicate that the use of the most common term in this classification 
system to describe severe anaphylactic events, “anaphylaxis”, has resulted in significantly more 
errors in mislabeling anaphylactic events as “other (not including serious)” events in comparison 
to the MedDRA classification system’s most common term to describe these events, 
“anaphylactic reaction”.  As discussed in Chapter 2, the CTCAE classification system grading 
severity levels only allow for the grading of “anaphylaxis” at grade levels three (severe), four 
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(life-threatening) and five (death).  Therefore, these events should only be included in the severe 
event table in ClinicalTrails.gov.  However, this was not the case as the results indicate there 
were significantly more CTCAE “anaphylaxis” events entered into the “other (not including 
serious)” table in comparison to the MedDRA terminology equivalent term “anaphylactic 
reaction” which was rarely mislabeled.  The possibility exists that the definition of the term 
“anaphylaxis” is not as well understood by clinical investigators in comparison to the MedDRA 
term.  Another possibility is the clinical investigators are labeling the severe grade 3 events 
which are described in the CTCAE version 4.0 Quick Reference as “severe or medically 
significant but not immediately life-threatening” as other than serious events due to the existence 
of only two permissible severity levels (severe or other) in this database. (U.S. Department of 
Health and Human Services, 2008) 
 
The lack of use of severity grading levels and the incorrect labeling of these events will impact 
the ability of public health and clinical research informatics investigators to study these severe 
events on a population level across clinical trials.  First and foremost, the ClinicalTrials.gov data 
will not be able to distinguish which clinical trial participants developed adverse hypersensitivity 
reactions which required immediate intervention for potentially life-threatening situations and 
study potential predictors for these events.  Secondly, the adverse events which resulted in death 
may not be captured correctly by the data without the level 5 designation which directly 
associates the hypersensitivity reaction with the adverse event.  Finally, if the population level 
researcher used only the severe adverse event table to study these severe events, the investigator 
would inadvertently not capture a large number of mislabeled events in the “other (not including 
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serious) table.  This would result in a much lower incidence rate of severe anaphylactic events 
secondary to clinical cancer trial drug and biological interventions. 
 
Hypothesis #2 
Severe allergic events recorded in ClinicalTrials.gov rarely (<5% of events) include the allergen 
responsible for the event which hinders the ability to study incidence when multiple drug or 
multiple therapeutic agents are used in clinical cancer trials.  In other words, there is no 
statistical difference between the most common terminologies used in this database regarding 
the inclusion of the drug allergen in the allergic event term. 
 
The first part of this hypothesis is true.  All terminology and classification systems, in addition to 
the events in which the terminology or classification system was not specified, rarely reported 
the allergen responsible for adverse event.  This was expected due to the terminology and 
classification systems used in capturing the severe anaphylactic and anaphylactoid events.  CTC, 
CTCAE, and MedDRA did not have the ability to code the event and the drug or biological agent 
responsible for the event.  However, in studying the adverse event table arms, there was not an 
ability to link the particular hypersensitivity event to a single drug in the multi-drug intervention 
arms.  For example, in Clinical Trial NCT00036738 which studies drug and radiation 
interventions for leukemia, the single arm trial treatment is listed as including the following:   
Arm/Group Title Treatment (Allogeneic Nonmyeloablative HSCT) 
Arm/Group Description:   
-Cyclosporine: Given IV or PO 
-Dasatinib: Given PO 
-Fludarabine Phosphate:  Given IV 
-Imatinib Mesylate:  Given PO 
-Mycophenolate Mofetil: Given PO 
-Nilotinib: Given PO 
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-Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo   
nonmyeloablative allogeneic PBSC transplantation 
-Peripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSC transplantation 
-Therapeutic Allogeneic Lymphocytes: Given IV 
-Total-Body Irradiation: Undergo TBI (U.S. National Library of Medicine, 2020) 
 
In this trial, one anaphylaxis event was record in the “Other (Not Including Serious) Adverse 
Events Table”, however, the treatment interventions for this arm in the table was only listed as 
“Allogenic Nonmyeloablative HSCT”.  Therefore, it was not possible to determine which 
intervention was the etiology of this event.  Generally, with severe hypersensitivity events, 
especially anaphylactic type events, there will be a close time association between the 
administration of the drug or agent and the event.  Therefore, without the ability to record or 
effectively link the drug or agent intervention to the event, this information will be lost in the 
transfer of the clinical trial data from the clinical investigator to the NLM ClinicalTrials.gov 
database.  The use of a terminology system such as RxNorm, which can capture the drugs in 
relation to the events could be helpful.  Furthermore, the use of a term which has the ability to 
enter in a specific drug or biological agent with the event, such as the recent guidance for 
collection of adverse infection events related to COVID-19.  On March 25, 2020, the Department 
of Health & Human Services Memorandum advised clinical investigators to use the term 
“Infections and infestations – Other, specify; specify = COVID-19”. (Mooney, Moscow, Ivy, & 
McCaskill-Stevens, 2020)  A similar approach could be used to capture the drug etiology or 
biological agent associated with the hypersensitivity event in clinical cancer trials.  For example, 
an additional field could be added for the immune category which requires the clinical 
investigator to specify which drug or agent was related or the likely etiology of the 
hypersensitivity event.  Interestingly in NCT00040485, a similar terminology method was used 
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to record a blood infection, “Infections and Infestations -Other (Blood). (U.S. National Library 
of Medicine, 2020) 
 
Regarding the second part of the hypothesis, there was no statistical difference between CTCAE, 
CTC and MedDRA with regards to inclusion of allergen discriptors within the adverse event 
term, however, there was a small statistical significant difference between the severe 
anaphylactic terms recorded using MedDRA terminology and those terms recorded with an 
unspecified terminology.   Statistical significance was also found between the categories of 
anaphylactic terms recorded using the CTC classification which included an allergen in 
comparison to the terms recorded using an unspecified terminology which included the allergen.  
This significance may be due to the increase in flexibility of clinical investigators entering free 
text within the adverse event tables.  For example, the term “Bactrim Anaphylaxis” was used 
which in not in the UMLS system, however, easily identified the cause of the anaphylactic 
reaction, the antibiotic sulfa drug, Bactrim.   
 
Hypothesis #3 
Over 25% of the severe allergic events have not been recorded using a systematic assessment 
method which could result in underreporting of events. 
 
The final hypothesis 3 was true, however, a large number of the clinical trials did not indicate 
their method of collecting adverse events.  In fact, a striking number of these trials, 76%, did not 
report their method of assessment.  Of the remaining 24% of clinical trials which did report 
collection methods for severe anaphylactic and anaphylactoid events, approximately 75% 
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collected their adverse events using a systematic assessment method.  Therefore, if you remove 
the unspecified category, the rate of systematic assessment collection method for cancer clinical 
trial severe anaphylactic and anaphylactoid adverse events was equal to 25%. 
 
The events recorded using the term “anaphylaxis” did not report their adverse event collection 
method for immune disorders in 93.6% of the cases, the overwhelming majority of cases.  This 
was in contrast to the MedDRA terminology reported events which used a systematic assessment 
collection method in the majority of cases (68.2%).  Therefore, investigators using MedDRA 
terminology were significantly more likely to report the use of a systematic method of 
assessment for adverse events, however, it is difficult to determine which terminology or 
classification system is more likely to use a systematic method given the large number of 
unspecified method type data points for events coded using the CTCAE and CTC classification 
systems. 
 
The impact of using a non-systematic collection method for adverse event reporting is the 
potential for not capturing events.  In a non-systematic assessment collection method, adverse 
immune events were not solicited by the clinical investigators and therefore, the events may or 
may not be reported by the clinical trial participant.  In a systematic assessment approach, the 
clinical investigators use a protocol or pre-determined method to periodically assess for potential 
adverse events such as a questionnaire or a diary. (National Institute of Health, 2020)  Therefore, 
without a protocol, even emergency room visits may be forgotten and not reported during the 
regularly scheduled clinical trial visits.  Under reporting of severe hypersensitivity events could 
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lead to inaccurately high drug safety assessments.  Therefore, the importance of rigorous adverse 
event collection methods of severe events cannot be overstated. 
 
Study Limitations 
As discussed above, a significant limitation of the study is the high number of severe 

















Chapter VI.  Conclusion 
 
The NCI CTCAE classification system was not found to improve the capture of severe 
hypersensitivity events in the case study of anaphylaxis and anaphylactoid events.  Lack of 
clinical investigator adoption of CTCAE terms with grades contributed to the inability to capture 
the severity level of anaphylactic or anaphylactoid events and resulted in no improvement in 
comparison to the previous use of CTC and MedDRA systems.  Furthermore, the CTCAE use of 
the term “anaphylaxis” resulted in a significant increase in miscoding of this adverse event 
severity level in comparison to the MedDRA equivalent term.  Furthermore, the lack of 
identification of the allergen etiology through the use of a term descriptor for these events in 
multi drug or multi interventional trials continues to be a significant problem which hinders the 
ability to use this data on a populations level for pharmacovigilance.  The overwhelming 
majoring of allergic reaction terms did not include the allergen and therefore, in dual or 
multi- drug therapies, the etiologic agent was not identifiable.  
 
To address these barriers to population level research of severe hypersensitivity events in clinical 
cancer trials, further research should be done to analyze the reason for lack of investigator 
adoption of the NCI CTCAE severity grade levels in severe hypersensitivity events.  
Furthermore, a return to the use of the MedDRA term “anaphylactic reaction” should be 
considered to avoid severity level confusion as this could make a significant impact on capturing 
severity events in research.  Also, further study and updating of CTCAE terms with a high 
percentage of miscoding of severity levels should be considered.  Furthermore, adapting terms 
which include the drug or at least the drug class could significantly improve the ability to capture 
  70
hypersensitivity event etiology.  This could advance the quality of data in population level study 
of anaphylaxis etiology and incidence in multi-drug cancer therapy, therefore, making a 
significant impact on the safety of these drugs.  Finally, systematic assessment adverse event 
collection methods should be used in clinical trials to reduce the possibility of underreporting of 
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Appendix A:  Cancer Drug and Biological Intervention Terms List 
Intervention  Drug Class Alternative names Abbreviatio
n 
Code name 


















cytarabine antimetabolite .beta.-Cytosine arabinoside, 
arabinofuranosylcytosine, 
arabinosylcytosine, aracytidine, beta-
cytosine arabinoside, cytarabine 
hydrochloride, cytarabinum, cytosine 








cetuximab monoclonalAB Anti-EGFR Monoclonal Antibody, 
Anti-Epidermal Growth Factor Receptor 
Monoclonal Antibody, 
C225 monoclonal antibody, 
Chimeric Anti-EGFR Monoclonal Antibody, 
Chimeric Monoclonal Antibody C225, 
anti-(human epidermal growth factor 
receptor) (human-mouse monoclonal C225 
gamma1-chain), disulfide with human-
mouse monoclonal C225 kappa-chain, dimer 





vincristine sulfate    plantAlkaloid leurocristine sulfate, vincristine sulfate, 





plantAlkaloid liposomal vincristine sulfate, vincristine liposomal, vincristine sulfate liposome 
injection, marqibo 
dexamethasone steroid Desamethasone, Dexamethasonum, 
































fludarabine antimetabolite fludarabine phosphate, fludarabine 
monophosphate 
2-F-ara-AMP SH T 586 
cisplatin platinum CACP, 
cis-DDP, 
cis-diamminedichloridoplatinum, 
cis-diamminedichloro platinum (II), 
cis-diamminedichloroplatinum, 
Cis-dichloroammine Platinum (II), 
Cismaplat, 
Cisplatina, 
cis-platinous diamine dichloride, 
cis-platinum, 
cis-platinum II, 












paclitaxel taxane Taxol TAX 
 
liposomal paclitaxel taxane LEP, liposome-encapsulated paclitaxel, 
paclitaxel liposome, LEP-ETU 
PNU-93914 
 
rituximab monoclonalAB BI 695500, 
C2B8 Monoclonal Antibody, 
CT-P10, 
IDEC-C2B8 monoclonal antibody, 
rituximab biosimilar ABP 798, 
rituximab biosimilar BI 695500, 
rituximab biosimilar GB241, 
rituximab biosimilar HLX01, 
rituximab biosimilar IBI301, 
rituximab biosimilar PF-05280586, 
rituximab biosimilar Reditux, 
rituximab biosimilar RTXM83, 

















docetaxel taxane Docefrez, 
Taxotere, 
Taxotere injection concentrate 
TXT RP 56976 











bendamustine alkalatingAgent bendamustin hydrochloride, CEP-18083, 
cytostasan hydrochloride, Treanda  
 
SDX-105 
everolimus mTORInhibitor 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, Zortress RAD001 
melphalan alkalatingAgent L-phenylalanine mustard, 
L-sarcolysin, 
L-sarcolysin phenylalanine mustard, 
L-sarcolysine, 
phenylalanine mustard, 








































sorafenib tyrosineKinaseInhibitor sorafenib tosylate, Nexavar SFN BAY 54-9085 
vinorelbine plantAlkaloid vinorelbine tartrate, navelbine ditartrate, 
vinorelbine ditartrate, Navelbine 
NVB KW-2307 
















carboplatin platinum Carboplatin Hexal, 
Carboplatino 
CBDCA JM-8 
ixabepilone antimicrotubuleAgent Azaepothilone B, 
epothilone B lactam, 
Epothilone-B BMS 247550, Ixempra 
 
BMS-247550 


































temozolomide alkylatingAgent Methazolastone, 
Temodar 
TMZ CCRG-81045, 
M & B 39831, 
RP-46161, 
SCH 52365 























































bevacizumab monoclonalAB anti-VEGF humanized monoclonal antibody, 
anti-VEGF monoclonal antibody, 
anti-VEGF rhuMAb, 
bevacizumab biosimilar BEVZ92, 
bevacizumab biosimilar BI 695502, 
bevacizumab biosimilar CBT 124, 
bevacizumab biosimilar FKB238, 
bevacizumab biosimilar PF-06439535, 
immunoglobulin G1 (human-mouse 
monoclonal rhuMab-VEGF gamma-chain 
anti-human vascular endothelial growth 
factor), disulfide with human-mouse 
monoclonal rhuMab-VEGF light chain, dimer 
recombinant humanized anti-VEGF 
monoclonal antibody, 





























gemcitabine antimetabolite gemcitabine hydrochloride,  dFdCyd 
 
irinotecan topoisomeraseInhibitor irinotecan hydrochloride, camptothecin-11, 




azacitidine antimetabolite 5-AC, 5-azacytidine, azacytidine, 




alvocidib kinaseInhibitor Afinitor, Zortress RAD001 
 
prednisolone steroid delta(1)hydrocortisone, delta1-dehydro-
hydrocortisone, deltahydrocortisone, 
metacortandralone, Cortalone, Delta-Cortef, 
Hydeltra, Hydeltrasol, Meti-derm, Prelone 
PRDL 
 
octreotide hormone octreotide acetate, Longastatin, Sandostatin, Sandostatin Lar 
Depot,  
SMS 201-995 
octreotide pamoate hormone ctreotide pamoate LAR(SMS 201-995), OP LAR, OncoLAR, 
Sandostatin pamoate, Sandostatin pamoate LAR 
SMS 201-995 pa, 
SMS 201-995 pa 
LAR 
vorinostat statin suberoylanilide hydroxamic acid, Zolinza SAHA L-001079038, 
MSK390 
idarubicin histoneDecetylaseInhibitor idarubicin hydrochloride, 4-
demethoxydaunomycin, 4-
demethoxydaunorubicin, DMDR, idarubicin 
HCl, Idamycin 
4-DMDR, IDA IMI-30, SC-
33428 

























monoclonalAB gemtuzumab ozogamicin, Calicheamicin-








pemetrexed antimetabolite pemetrexed disodium, multitargeted 
antifolate, Alimta 
MTA LY231514 
topotecan topoisomeraseInhibitor liposomal topotecan hydrochloride, topotecan hydrochloride liposomes, Brakiva 
pomalidomide immunomodulatoryAgent Pomalyst 
 
CC-4047 
thymocyte antithymocyte anti-thymocyte globulin, lymphocyte 
immune globulin, ATGAM, Thymoglobulin 
ATG   
capecitabine antimetabolite Xeloda CAPE Ro 09-1978/000 





nilotinib tyrosineKinaseInhibitor Tasigna   AMN 107 
belinostat histoneDecetylaseInhibitor Beleodaq   PXD 101, 
PXD101 
thioguanine antimetabolite tioguanin, tioguanine, Tabloid 6-TG, TG BW 5071, 
Wellcome, U3B, 




ipilimumab monoclonalAB anti-cytotoxic T-lymphocyte-associated 
antigen-4 monoclonal antibody, MOAB 
CTLA-4, monoclonal antibody CTLA-4, Yervoy 
MDX-CTLA-4 BMS-734016, 
MDX-010 
dacarbazine alkylatingAgent Biocarbazine, Dacarbazina, Dacarbazina 
Almirall, Dacarbazine - DTIC, Dakarbazin, 
Dimethyl (triazeno) imidazolecarboxamide, 
Dimethyl Triazeno Imidazol Carboxamide, 
Dimethyl Triazeno Imidazole Carboxamide, 
Imidazole Carboxamide, 
Imidazole Carboxamide Dimethyltriazeno, 
DTIC-Dome 
DIC, DTIC WR-139007 
ganetespib other Hsp90 inhibitor STA-9090   STA-9090 
temsirolimus mTORInhibitor cell cycle inhibitor 779, rapamycin analog CCI-779, Torisel CCI-779 







plantAlkaloid albumin-bound paclitaxel, 
Albumin-Stabilized Nanoparticle Paclitaxel, 
nab paclitaxel, 
nab-paclitaxel, 
nanoparticle albumin-bound paclitaxel, 
Nanoparticle Paclitaxel, 
protein-bound paclitaxel, Abraxane 
 
ABI-007 
eribulin microtubuleInhibitor halichrondrin B analog, Halaven B1939 mesylate, 
E7389, 
ER-086526 
cediranib tyrosineKinaseInhibitor AZD2171 maleate, Recentin 
 
AZD2171 
entinostat histoneDecetylaseInhibitor HDAC inhibitor     
lomustine alkylatingAgent Lomustinum, Gleostine CCNU RB-1509, WR-
139017 
thalidomide immunomodulatoryAgent alpha-phthalimidoglutarimide, 
N-phthaloylglutamimide, 
N-phthalylglutamic acid imide, Thalomid 
THAL 
 
arsenic trioxide other arsenic trioxide formulation ORH 2014, 
As2O3 formulation ORH 2014, 
oral arsenic trioxide formulation 
 
ORH-2014 


















phenylbutyric acid nitrogen mustard, 
Ambochlorin, Amoclorin, Leukeran, Linfolizin 
CHL, CLB CB-1348, WR-
139013 
afimoxifene hormoneInhibitor 4-Hydroxy-Tamoxifen 
  
tamoxifen hormoneInhibitor tamoxifen citrate, tamoxifeni citras, 
Nolvadex 
TAM ICI 46,474, 
ICI-46474 
trabectedin alkylatingAgent ecteinascidin, Yondelis ET 743 
 





ramucirumab monoclonalAB anti-VEGFR-2 fully human monoclonal 








nivolumab monoclonalAB anti-PD-1 human monoclonal antibody MDX-


















sunitinib tyrosineKinaseInhibitor sunitinib malate, Sutent SU11248 SU011248, 
SU011248, 
SU11248 
panitumumab monoclonalAB clone E7.6.3, 
monoclonal antibody ABX-EGF, Vectibix 
MOAB ABX-EGF ABX-EGF 
pazopanib tyrosineKinaseInhibitor pazopanib hydrochloride, Votrient 
 
GW786034B 
thioplex alkylatingAgent thiotepa, thiofosfamide, thiophosphamide, 
thiophosphoramide, triethylene 
thiophosphoramide 
TSPA WR 45312 
alemtuzumab monoclonalAB anti-CD52 monoclonal antibody, 
Campath-1H, 
Monoclonal Antibody Campath-1H, 
Monoclonal Antibody CD52, Campath 
MoAb CD52 
 
muromonab monoclonalAB muromonab-CD3, Anti-CD3 monoclonal 
antibody OKT3, 
MOAB OKT3, 
monoclonal antibody OKT3, 
OKT3, Orthoclone OKT3 
MOAB OKT3 
 




pravastatin* statin pravastatin sodium, Pravachol PRAV 
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            Role:  Co-investigator 
            Dates:  3/1/2013 - 11/1/2013 




Speaker, “Applied Health Informatics Master’s Level Education:  A Discussion of Core 
Competencies”, HIMSS20 Lightening Session, occurring March 12, 2020. 
 
 
Keynote Speaker, “Connected Health:  How your smartphone can manage your health”, 
Information Day, University of South Florida School of Information 
April 25, 2018. 
 
Pediatric Food Allergy Management in the Community. CME Presentation.  The Medical 
College of Wisconsin Department of Family and Community Medicine’s 45nd Annual 
Winter Refresher Course for Family Medicine. Waukesha, WI, January 30, 2015. 
Guest Lecturer, Translational Science and Translational Biomedical Informatics, 
Milwaukee School of Engineering Biomolecular Engineering (BioE) Program  
Seminar Course, January 13th, 2015 
 
2014 Catholic Educators Convention, Leading the Learning 
Presented:  Food Allergy Update 
Frontier Airlines Center, Milwaukee, October 10th, 2014. 
Guest Lecturer, Clinical Research Informatics Case Presentation, 
Milwaukee School of Engineering Medical Informatics Case Study Course:  September 
19th, 2013, MSOE, Milwaukee, WI, September 15th, 2014, MSOE, Milwaukee, WI, 
October 22nd, 2015, MSOE, Milwaukee, WI 
 
  89
mHealth:  Using Mobile Technology to Connect with Your Patient.  The Medical College 
of Wisconsin Department of Family and Community Medicine’s 44nd Annual Winter 
Refresher Course for Family Medicine. Waukesha, WI.  February 5th, 2014. 
2012 Catholic Educators Convention, Catholic Schools: A Commitment to Excellence 
Presented:  Managing Food Allergies in the Classroom 
Frontier Airlines Center, Milwaukee, October 12th, 2012. 
Facilitator, Community Health Informatics Workshop, Information Technology 
Resources for Research Breakout Session, University of Wisconsin-Milwaukee School of 
Continuing Education Conference Center, Tuesday October 2, 2012, Milwaukee, WI. 
 
Pediatric Food Allergy:  School-Based Management. CME Presentation.  The Medical 
College of Wisconsin Department of Family and Community Medicine’s 42nd Annual 
Winter Refresher Course for Family Medicine. Waukesha, WI.  February 3rd, 2012. 
 
 






Golam M. Tanimul Ahsan, Christina Eldredge, MD MS; Brenda White, EdS; Zeno 
Franco, PhD; Sheikh I. Ahamed, PhD.  mHealth for School Emergency Preparedness.  
Clinical & Translational Science Institute of Southeast Wisconsin’s Community Health 
Informatics Workshop, Milwaukee, WI, May 30, 2013. 
 
Eldredge CE, Patterson L, Schellhase K. Implementation of Food Allergy Management 
Policies in Private Schools.  20th Annual Department of Family and Community 





Patterson L, Morzinski J, Eldredge CE. Using Veterans as Peer-Group Health Workers 
to Improve Hypertension Awareness and Management. 2011 Wisconsin Public Health 
Association and Wisconsin Association of Local Health Departments and Boards Annual 





Eldredge C., Andrews J.E., Zolnoori M., Patrick T., Gallagher J., Lam C. and J. Luo.  
Challenges to a Data Driven Approach to Population Level Analysis of Hypersensitivity 
Events in Cancer Clinical Trials.  Poster presented at the AMIA Annual Symposium, 
November 19, 2019, Washington, D.C. 
 
  90
Lam C., Eldredge C., Andrews J., Perkins R.  Challenges to Data Abstraction to 
Characterize Contrast Media Reactions and Identify Potential Risk Factors in a Cancer 
Patient Population.  Poster presented at the AMIA Annual Symposium, November 19, 
2019, Washington, D.C. 
 
Lam C., Eldredge C., Andrews J.E. and Perkins R. Adverse Contrast Media Event 
Documentation: A Cancer Center Perspective. Poster presented at the AMIA Clinical 
Informatics Conference, April 30 – May 2, 2019, Atlanta, GA. 
 
Andrews J.E., Eldredge C, and Cooperman C. Building an Institute for Health Sciences 
Information (Ihsi): Connecting Education, Industry, and Research. Accepted to the 
AMIA InSpire 2017: Developing the Health Informatics Workforce of the Future 
conference, La Jolla, CA, June 6-8, 2017. 
 
Joel Gallagher; Robert Rivera; Asriani Chiu; Tanvir Roushan; Golam Mushih Tanimul 
Ahsan; Cheng Wen; Christina Eldredge; Sheikh Iqbal Ahamed. “The Use of a mHealth 
Decision Tree Support Program for Epinephrine Auto-injector (EAI) Administration 
Training of Adolescents” AMIA 2016 Annual Symposium Conference Proceedings, 
Washington DC, Nov. 15, 2016. 
 
Eldredge, Christina; Ahsan, Golam Mushih Tanimul; Chiu, Asriani; White, Brenda; 
Atchison, Taylor; Patterson, Leslie; Ahamed, Sheikh Iqbal.  “Pilot assessment of a 
caregiver decision support mobile health (mHealth) application for food allergy & 
anaphylaxis in the school environment.”  AMIA 2014 Annual Symposium Conference 
Proceedings, Washington DC, Nov. 15-19, 2014. 
 
Christina Eldredge, MD MS; Golam M Tanimul Ahsan; Zeno Franco, PhD; Brenda 
White, Ed.S.; Asriani  M. Chiu, MD; Leslie Patterson, PhD MS; Mohammad Arif Ul 
Alam; Sheikh Iqbal Ahamed, PhD.  mHealth for School Food Allergy Emergency 
Preparedness.  mHealth Summit.  Washington D.C. December 2013. 
 
Slawson J, Eldredge CE, Hughes J, Payne J, Olsen S, Leienger M.  Benefits of a Patient 
Centered Medical Home for High Risk OB Care:  A first year preliminary report.  5th 
Annual National CTSA Community Engagement Conference, “Methods, Metrics and 
outcomes:  Evaluating the Success of Community Engaged Research”, Bethesda, MD, 
August 23rd-24th, 2012. 
 
Eldredge CE, Slawson J, Granados R, Payne J.  Developing a Combined Research and 
QI Database from Community Based Practices with Different IT Systems. 4th Annual 
National CTSA Community Engagement Conference, “Using IT to Improve Community 
Health:  How Health Care Reform Supports Innovation”.  Bethesda, MD, August 30th-
31st, 2011. 
 
Morzinski J., Patterson L., Eldredge CE. Teaching Community Health Workers to Train 
Peers About Hypertension: Outcomes & Implications. Society of Teachers of Family 





Zolnoori, M., Patrick, T. B., Fung, KW., Fontelo P., Faiola, A., Wu YS. S., Xu, K., Zhu, 
J., Eldredge, C. E. Development of an Adverse Drug Reaction Corpus from Consumer 
Health Posts. Workshop: American Medical Informatics Association, Annual Symposium, 
Washington, DC., November, 2017.  http://ceur-ws.org/Vol-1996/paper3.pdf 
  
Lam CA, Eldredge C, Taylor B, Ahmed N, Kahn C.   Feasibility of a Generalized 
Informatics Framework for Cohort Identification, Hypothesis Generation, and 
Retrospective Data Analysis for Radiology Research - Educational Exhibit.  Chicago, IL, 




National Oral Presentations 
 
Zolnoori M., Ngufor C., Faiola A., Eldredge C., Luo J., Sunghwan S., Balls-Berry J.E., 
Tafi A.P., Shah N.D., Patrick T.B.  Identifying Factors Affecting Drug Discontinuation in 
Patients with Depression:  Text Analysis of Patient Drug Review Post.  Podium Abstract 
presented at the AMIA Annual Symposium, November 19, 2019, Washington, D.C. 
  
Eldredge C, Singavi A, Lam C, Gallagher J and Luo J.  Big Data Analysis of Drug 
Induced Hypersensitivity and Anaphylaxis Reactions in Clinical Cancer Trails.  
AAAAI/WAO, Orlando, FL, March 3, 2018.  Journal of Allergy and Clinical 
Immunology, Vol 141, Issue 2, Supplement, Page AB87. 
 
Lam CA, Eldredge C, Sawlani R, Bushee G, Taylor B, Kahn C. Assessing the Validity of 
Contrast Induced Nephropathy Using the i2b2 Informatics Framework: A Retrospective 
3-year Electronic Medical Record Review. Oral Paper Presentation.  Chicago, IL, RSNA 
2014. 
 
MEDICAL COLLEGE TEACHING ACTIVITIES: 
 
 Community/Lay Public 
 2011 Archdiocese of Milwaukee School Staff Medication Training Day 
 
 Medical Student Education 
2012-2014    Instructor, M1 Foundations of Clinical Medicine course 
2011-2014    Instructor, CHCR Family Medicine Clerkship 
2011-2012    Instructor, Medical Interviewing 
2010-2013    Facilitator, Medical Student Intercessions  
2010-2013    Facilitator, Urban and Community Health Pathway 
 




6/2012 – 9/2012  Medical College of Wisconsin, M2 Summer Research Internship Student 
9/2011 – 5/2014  Medical College of Wisconsin, Urban and Community Pathway Student 
9/2012 – 5/2018  Medical College of Wisconsin, Quality Improvement Pathway Students 
 
Masters Students and Fellows: 
2014 – 2015 Marquette Computer Science Student, member of Masters’ Thesis 
Committee 
2014 – 2017 Medical College of Wisconsin Allergy and Immunology Fellow, 
member of his Scholarly Oversight Committee and mentor for a mobile 
health project 
2016 - 2018 Medical College of Wisconsin, Hematology and Oncology Fellow, 




Maryam Zolnoori; Kin Wah Fung; Timothy Patrick; Paul Fontelo; Hadi Kharrazi; 
Anthony  Faiola; Yi Shuan Shirley  Wu; Christina E.  Eldredge; Jake Luo; Mike Conway; 
Jiaxi Zhu; Soo Kyung Park; Kelly Xu; Hamideh Moayyed.  (2019, March 21). The PsyTAR 
Dataset:  From Patients Generated Narratives to a Corpus of Adverse Drug Events and 
effectiveness of Psychiatric Medications.  Data in brief. 24:103838.  PMID:  31065579 
 
Maryam Zolnoori; Kin Wah Fung; Timothy Patrick; Paul Fontelo; Hadi Kharrazi; 
Anthony  Faiola; Yi Shuan Shirley  Wu; Christina E.  Eldredge; Jake Luo; Mike Conway; 
Jiaxi Zhu; Soo Kyung Park; Kelly Xu; Hamideh Moayyed; Somaieh Goudarzvand.  (2019, Jan 3) 
A Systematic Approach for Developing a Corpus of Patient Reported Adverse Drug Events: A 
Case Study for SSRI and SNRI Medications.  Journal of Biomedical Informatics. PMID:  
30611893 
 
Annette L Valenta, Eta S Berner, Suzanne A Boren, Gloria J Deckard, Christina Eldredge, 
Douglas B Fridsma, Cynthia Gadd, Yang Gong, Todd Johnson, Josette Jones, E LaVerne Manos, 
Kirk T Phillips, Nancy K Roderer, Douglas Rosendale, Anne M Turner, Guenter Tusch, Jeffrey J 
Williamson, Stephen B Johnson.  (2018, Dec. 1) AMIA Board White Paper: AMIA 2017 core 
competencies for applied health informatics education at the master’s degree level.  Journal of 
the American Medical Informatics Association, 25 (12):  1657-1668.  PMID:  30371862 
 
Gallagher JL, Rivera RD, Van Shepard K, Roushan T, Ahsan G, Ahamed SI, Chiu A, Jurken M, 
Simpson PM, Nugent M, Gobin KS, Wen CKF, and Eldredge CE. (2018, Jul 3). Life-
Threatening Allergies:  Using a Patient-Engaged Approach.  Telemedicine Journal and e-Health. 
PMID: 29969372 
 
Luo J, Eldredge C, Cho CC, Cisler RA.  (2016) Population Analysis of Adverse Events in 




Jackson J, Cogbill E, Santana-Davila R, Eldredge C, William C, Gradell A, Sehgal N, Kuester J. 
(2015, Jul 14) A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of 
Migraine Headache.  PLOS ONE, 10(7): E0130733.  PMID:  26172390 
 
Eldredge C, Patterson L, White B, Schellhase K. (2014, Aug) Assessing the Readiness of a 
School System to Adopt Food Allergy Management Guidelines. Wisconsin Medical Journal, 113 
(4); 155-161. PMID:  25211803 
 
Bradford L, Eldredge CE, Morzinski, JA. (2013, Feb) Training community-engaged 
researchers. Academic Medicine, 88(2):154.  PMID: 23361025 
 
Eldredge CE and Schellhase K.  (2012, Jul 1) School-Based Management of Food Allergies in 
Children.  American Family Physician, 86(1), 16-18.  PMID: 22962908 
 
Marriott LK, Nelson DA, Allen S, Allen, S. Calhoun, K. Eldredge CE. Kimminau KS. Lucero 
RJ. Pineda-Reyes F. Rumala BB, Varanasi, AP, Wasser, JS, Shannon J. (2012, Feb. 1) Using 
health information technology to engage communities in health, education, and research. Science 
Translational Medicine, 4(119), 119mr111.  PMID:  22301550 
 
Kahn CE, Jr., Kalpathy-Cramer J, Lam CA, Eldredge CE. Accurate Determination of Imaging 
Modality using an Ensemble of Text- and Image-Based Classifiers. (2011, Jul 6)  Journal of 




Andrews, J. E., Johnson, J.D., & Eldredge, C. (2019). The evolving roles of consumers. In R. 
Richesson & J.E. Andrews (Eds). Clinical Research Informatics. Springer-Verlag: London 2nd 
ed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
